B005-TMIMI-editorial
系统生物学方法在骨质疏松症中医证候研究中的应用

ʌ述评ɔ系统生物学方法在骨质疏松症中医证候研究中的应用❋章轶立1,2,齐保玉1,魏㊀戌1ә,戴建业3,王㊀旭1,申㊀浩4,谢雁鸣5(1.中国中医科学院望京医院,北京㊀100102;2.北京中医药大学中医学院,北京㊀100029;3.兰州大学药学院,兰州㊀730020;4.北京市丰台区长辛店社区卫生服务中心,北京㊀100072;5.中国中医科学院中医临床基础医学研究所,北京㊀100700)㊀㊀摘要:随着现代科学技术的进步及证候学研究的逐步深入,借助系统生物学的方法研究骨质疏松症中医证候以阐释证候科学内涵的研究逐年增多㊂本研究发现,目前骨质疏松症相关证候的基因组学与蛋白质组学研究仍停留在单个基因层面,主要包括骨钙素基因㊁雌激素受体基因以及Smad ㊁β-catenin 等蛋白,并未从整体的角度探究证候发生㊁发展的本质问题㊂代谢组学方面,虽然通过对骨代谢指标相关产物的检测,发现了与证候相关的代谢指标,但对于骨代谢终端产物的组学研究较少㊂未来研究仍需进一步运用组学技术手段,全方位㊁多层次㊁宽视角的探讨骨质疏松症中医证候的发生发展规律㊂㊀㊀关键词:骨质疏松症;证候;系统生物学;组学㊀㊀中图分类号:R2-03㊀㊀文献标识码:A㊀㊀文章编号:1006-3250(2021)04-0703-04Application of Systematic Biology Method in Traditional Chinese Medicine SyndromesResearch of OsteoporosisZHANG Yi-li 1,2,QI Bao-yu 1,WEI Xu 1ә,DAI Jian-ye 3,WANG Xu 1,SHEN Hao 4,XIE Yan-ming 5(1.Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100102,China;2.Beijing University of Chinese Medicine,Beijing 100029,China;3.School of pharmacy,Lanzhou university,Lanzhou 730020,China;4.Changxindian Community Health Service Center of Fengtai District,Beijing 100072,China;5.Institute of BasicResearch and Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China)㊀㊀Abstract :With the progress of science and technology and the gradual deepening of syndrome research ,the research on TCM syndromes of osteoporosis with the help of the method of systematic biology is increasing year by year.This study found that at present ,the genomic and proteomic studies of osteoporosis-related syndromes are still at the level of a single gene ,mainly including osteocalcin gene ,estrogen receptor gene ,Smad ,β-catenin and other proteins ,but fail to explore the nature of the occurrence and development of osteoporosis syndrome as a whole.In the aspect of metabolomics ,although the metabolites related to TCM syndrome have been found ,there are few studies on the end products of bone metabolism.Future research still needs to further use multi-omics technology to further explore the occurrence and development of TCM syndromes of osteoporosis.㊀㊀Key words :Osteoporosis ;Traditional Chinese medicine syndrome ;Systematic biology ;Omics❋基金项目:国家中医临床研究基地项目第二批科研专项(JDZX2015076)-中医综合干预方案预防原发性骨质疏松症骨折的前瞻性队列研究;中国中医科学院优秀青年科技人才(创新类)培养专项(ZZ13-YQ-039)-中医药防治脊柱退行性疾病的临床与基础研究;中国中医科学院循证能力提升建设项目(ZZ13-024-7)-骨伤科疾病中医药优先主题设置及循证研究实施方案设计;中国博士后科学基金(2019M662284)-基于多组学技术探究补肾中药治疗骨质疏松症的共有机制;中华中医药学会(2017 2019年度)青年人才托举工程项目(CACM-2017-QNRC2-A03)作者简介:章轶立(1991-),男,安徽芜湖人,在读博士研究生,从事老年病中医证候及中医药临床评价方法研究㊂ә通讯作者:魏㊀戌(1985-),男,四川绵阳人,研究员,博士研究生,博士研究生导师,从事骨关节退变与骨代谢疾病的临床与基础研究,Tel :134****6557,E-mail :weixu.007@ ㊂㊀㊀骨质疏松症(osteoporosis ,OP )主要表现为骨代谢异常,以全身性骨痛和易发生脆性骨折为特征性表现,与增龄关系密切,发病率呈逐年递增趋势[1]㊂中医药在提高OP 患者骨密度㊁改善临床症状㊁促进骨质疏松性骨折愈合等方面具有一定的优势[2-3]㊂证候作为中医临床诊治的重要依据,是中医学研究中的核心要素与学理支点[4]㊂系统生物学是研究生物系统中所有组分(如基因㊁蛋白质㊁代谢产物等)构成,以及在特定条件下(如遗传㊁环境变化等)各组分之间相互关系的学科,以多种组学技术为代表,为阐释中医证候生物学基础与辨证论治的科学内涵提供了重要的方法学支撑[5-7]㊂现就近年来系统生物学方法在OP 中医证候研究中的应用进行述评㊂1㊀基因组学研究基因组学关注微观的㊁相对稳定的生物基因精确结构㊁相互关系及表达调控,强调基因表达的差异是造成个体差异的主要原因㊂证候基因组学是在中医证候学理论指导下,运用基因组学的方法探讨OP 中医证候的科学内涵,特别是研究同病异证或异病3072021年4月第27卷第4期April 2021Vol.27.No.4㊀㊀㊀㊀㊀㊀中国中医基础医学杂志Journal of Basic Chinese Medicine同证时基因的差异表达情况,揭示与证候形成相关的基因及其功能[8-9]㊂肾藏精,主骨生髓,肾虚证与OP发病关系密切㊂郑洪新等[10]通过实验证实,OP肾虚证病理机制与转化生长因子β1(transforming growth factor-β1,TGF-β1)㊁TGFβ诱导早期应答基因1(TGF-βinducible early gene,TIEG1)mRNA等表达异常有关,并运用补肾益髓中药发挥对下丘脑-肾-骨反馈机制的调控作用以预防OP的发生发展㊂尚德阳等[11]发现,OP的发生可能与骨㊁肾㊁下丘脑组织中Smad泛素化调节因子1(Smad ubiquitination regulatory factor1,Smurf1)和Smad泛素化调节因子2(Smad ubiquitination regulatory factor2,Smurf2)的mRNA表达的异常变化有关,补肾中药可能通过调控上述因子表达发挥防治OP的作用㊂王爱坚等[12]研究提示,载脂蛋白E等位基因ε4频率升高与绝经后妇女肾虚证发生关系密切,肾虚证与载脂蛋白E基因多态性存在联系㊂在绝经后OP易感基因与基因多态性研究方面,国内葛继荣教授团队前期研究结果表明,OP证候与遗传特征可能存在关联性,在维生素D受体基因bb型中,绝经后OP肾阴阳两虚证腰椎骨密度明显低于肾阴虚证患者[13]㊂另有研究证实[14-15],绝经后OP肾阳虚证与骨钙素基因多态性㊁雌激素受体基因多态性存在关联,而肾阴虚证的发生与lncRNA uc431+的表达下调㊁富亮氨酸2糖蛋白1(leucine-rich-alpha-2-glycoprotein1,LRG1)的mRNA表达升高有关[16-18]㊂研究还发现,LINC00334等8条lncRNAs可能通过调控Janus激酶/信号传导与转录激活子(janus kinase/signal transducer and activator of transcription,JAK/STAT)信号通路㊁丝裂原活化蛋白激酶(mitogen-activated protein kinases,MAPKs)等信号通路参与绝经后OP肾阴虚证的发生发展过程[19]㊂此外,李颖等[20]研究发现,绝经后OP中医证候与线粒体DNA拷贝数㊁DNA氧化损伤的产物8 -羟基脱氧鸟苷酸含量存在相关性,其中肝肾阴虚证与线粒体DNA拷贝数相关性高,脾肾阳虚证与8 -羟基脱氧鸟苷酸关系密切㊂李生强等已完成对原发性骨质疏松症肾阴虚证㊁肾阳虚证骨组织基因表达谱的测定,不同肾虚证候相关基因均与免疫调节相关,肾阴虚证基因还与激素合成㊁组氨酸代谢㊁矿物质吸收等通路相关,而肾阳虚证基因还与TGF-β㊁细胞周期等信号通路相关[21-22]㊂基于现有文献,目前针对OP证候的基因组学研究主要停留在个别基因对OP证候的关联,并未从整体的角度探究OP证候发生发展的本质问题,未来研究仍需构建OP非肾虚证候相关的基因差异表达谱,筛选出与之有关的基因,并从功能基因组学的角度对其调控网络进行分析㊂同时,从 同病异证 和 同证异病 的角度比较基因表达谱的差异,寻找OP证候的同一性和差异性,进而揭示OP证候的科学内涵,并为其客观化诊断提供依据㊂2㊀蛋白质组学研究蛋白质组学是对基因组学的继承与发展,可系统分析细胞内动态变化的蛋白质组成㊁表达水平和修饰状态,了解蛋白质之间存在的相互关系,揭示蛋白质功能与细胞生命活动规律[23-24]㊂证候蛋白质组学研究有助于获得疾病证候的生物学实质与生物标志物,进一步使证候研究走向客观化与标准化[25]㊂国内学者已初步发现绝经后OP肾阳虚证与LTBP1蛋白表达下调相关联,而肾阴虚证与CLCFI 蛋白下调存在关联[26-28]㊂王蕾等[29]研究发现,破骨细胞相关因子蛋白表达水平与肾阳虚证㊁脾胃虚弱证㊁肝肾阴虚证㊁气滞血瘀证具有相关性㊂其中,巨噬细胞集落刺激因子㊁核因子κB受体活化因子可作为区别肾阳虚证与其他证候的生物标志物㊂邓洋洋等[30]发现,肾虚OP模型大鼠Smurf1蛋白在股骨㊁肾中表达降低,在下丘脑中表达水平升高,而补肾中药可能通过调控股骨㊁肾㊁下丘脑中Smurf1表达发挥防治原发性OP的作用㊂章建华等[31-32]运用左归丸与右归丸含药血清,对去卵巢大鼠肾阴虚证与肾阳虚证动物模型进行干预,结果证实两方均能促进成骨细胞增殖与碱性磷酸酶表达水平,并对细胞外调节蛋白激酶(extracellular regulated protein kinases,ERK)与β-catenin的蛋白表达具有一定调控作用㊂此外,对比不同动物模型中蛋白表达水平发现, 左归丸滋肾阴 作用更强,而 右归丸温肾阳 作用更强,与中医理论相符㊂伍超等[33]结合网络药理学与实验验证,发现肾精亏虚证可能与促红细胞生成素(erythropoietin,EPO)信号通路中低氧诱导因子-1(hypoxia inducible factor-1,HIF-1)㊁生长因子受体结合蛋白2(growth factor receptor-bound protein2,GRB2)㊁MAPK3等蛋白密切相关,而补肾益精中药通过调控EPO信号通路中靶点蛋白水平的降低,可能是治疗肾精亏虚证的作用机制之一㊂另1项研究表明,电针命门穴可促进骨形态发生蛋白(bone morphogenetic protein-2,BMP-2)及其信号传导蛋白Smad1/5表达水平,为电针治疗绝经后OP提供了基础研究证据[34]㊂与证候基因组学的研究现状相似,OP证候层面的蛋白质组学研究仍然集中于对疗效机制的科学阐释,多数聚焦于补肾类中药可能作用的靶点㊂而从证候衍变规律角度出发,探索证候动态变化及其生物学内涵的相关研究还不够深入,尚未形成完整的OP证候蛋白质组学证据链㊂3㊀代谢组学研究代谢组学是对生物体内的代谢物进行定量分析,试图寻找代谢物与生理病理变化相对关系的研407中国中医基础医学杂志Journal of Basic Chinese Medicine㊀㊀㊀㊀㊀㊀2021年4月第27卷第4期April2021Vol.27.No.4究,也是系统生物学的重要技术方法之一[35-36]㊂OP 属于全身代谢性疾病,代谢组学为OP临床诊断和治疗提供了一种整体的方法,对深入理解OP病理机制及中药等干预机制具有重要作用[37]㊂证候代谢组学通过测定不同证候间代谢产物的差异,为证候生物学基础研究开辟了新途径㊂徐琬梨等[38]应用核磁共振氢谱技术测定绝经后OP常见实证(肾虚对照组㊁肾虚血瘀组㊁肾虚痰湿组㊁肾虚气滞组)血清代谢产物,结果表明各组间存在差异代谢物,主要生物学功能涉及体内能量代谢㊁氨基酸代谢㊁蛋白代谢等方面,证实不同中医证候与代谢产物密切相关㊂张波等[39]通过OP肾虚血瘀证与骨质疏松症常规检测指标相关性研究证实,OP肾虚血瘀证可能与血清Ⅰ型胶原C末端肽㊁骨密度㊁25羟维生素D㊁雌二醇等具有相关性㊂帅波等[40]研究证实,骨转换标志物β-骨原交联㊁血清白细胞介素-6㊁肿瘤坏死因子含量与中医 本痿标痹 证候评分存在正相关,建议骨代谢与炎症指标可作为OP进展评价及疗效判定的依据㊂当前多数研究虽然通过对骨代谢指标相关产物检测,发现与OP证候相关的部分代谢指标,但针对骨代谢终端产物的代谢组学研究依然较少㊂此外,在中医药干预OP的作用机制研究中,虽然应用了代谢组学方法,但因与证候关联性较弱,因此未引用相关原始研究文献㊂除应用基因组学㊁蛋白质组学㊁代谢组学方法研究OP证候外,还有学者运用表观遗传学方法研究中医证候,主要表观遗传机理是miRNA㊁DNA甲基化,但相关研究仍处于探索阶段[41]㊂4 讨论随着生命科学大数据时代的到来,组学技术广泛运用于中医中药研究,各种组学方法已在证候生物学基础研究方面取得了积极进展[43]㊂系统生物学因其强调整体性㊁时效性的特点与中医学整体观念㊁辨证论治的思想较为吻合[44],借助系统生物学的方法与思路,不仅丰富了OP证候的理论内涵,拓宽了研究思路,也有助于搭建微观研究(基因㊁蛋白㊁代谢组学研究)与整体研究(证候研究)的桥梁,为OP证候客观化提供科学依据[45]㊂尽管目前运用系统生物学进行OP证候本质研究尚处于探索㊁发展阶段,但基于系统生物学特点㊁研究思路㊁技术方法为OP证候本质的研究带来了新的方向[46-47]㊂因此,将系统生物学运用于OP证候研究,建立多方向㊁多层次的组学技术平台,并通过计算生物学等数学语言定量描述生物体功能㊁表型及行为,对揭示OP证候本质具有重要意义,进而促进中医药现代化研究进程㊂参考文献:[1]㊀QASEEM A,FORCIEA MA,MCLEAN RM,et al.Treatment ofLow Bone Density or Osteoporosis to Prevent Fractures in Menand Women:A Clinical Practice Guideline Update From theAmerican College of Physicians[J].Ann Intern Med,2017,166(11):818-839.[2]㊀LIU Y,LIU JP,XIA Y.Chinese herbal medicines for treatingosteoporosis[J].Cochrane Database Syst Rev,2014,(3):CD005467.[3]㊀LIAO HH,YEH CC,LIN CC,et al.Prescription patterns ofChinese herbal products for patients with fractures in Taiwan:Anationwide population-based study[J].J Ethnopharmacol,2015,173:11-19.[4]㊀刘进娜,谢鸣,赵静,等.基于系统生物学和病证结合模型对中医证候表征的研究[J].中国科学㊃生命科学,2016,46(8):913-928.[5]㊀WANG X,ZHANG A,SUN H,et al.Systems biologytechnologies enable personalized traditional Chinese medicine:asystematic review[J].Am J Chin Med,2012,40(6):1109-1122.[6]㊀孙安会,袁肇凯,夏世靖,等.中医证候系统生物学研究的现状和展望[J].中华中医药杂志,2016,31(1):200-204. [7]㊀BURIANI A,GARCIA-BERMEJO ML,BOSISIO E,et al.Omictechniques in systems biology approaches to traditional Chinesemedicine research:present and future[J].J Ethnopharmacol,2012,140(3):535-544.[8]㊀GU P,CHEN H.Modern bioinformatics meets traditionalChinese medicine[J].Briefings in Bioinformatics,2014,15(6):984-1003.[9]㊀何清湖,周兴.从中西医学的异同探讨中医证候基因组学[J].湖南中医药大学学报,2012,32(3):3-5.[10]㊀郑洪新,燕燕,王思程,等. 肾藏精生髓主骨 藏象理论研究 肾虚骨质疏松症大鼠转化生长因子相关基因及蛋白表达的异常[J].世界科学技术 中医药现代化,2010,12(1):57-64.[11]㊀尚德阳,邓洋洋,孙鑫,等.补肾中药对肾虚骨质疏松症大鼠骨㊁肾㊁下丘脑组织中Smurf1/Smurf2的mRNA表达影响[J].中华中医药杂志,2015,30(10):3629-3633.[12]㊀王爱坚,王大健,裴云,等.绝经后肾虚证与骨代谢㊁雌激素及ApoE基因多态性的相关性研究[J].辽宁中医杂志,2011,38(10):1948-1950.[13]㊀葛继荣,李生强,朱小香,等.不同中医证型及维生素D受体基因BsmⅠ多态性与绝经后骨质疏松症患者骨密度的关系[J].中国组织工程研究,2006,10(15):42-44.[14]㊀李生强,谢冰颖,谢丽华,等.绝经后骨质疏松症肾虚证与基因多态性的相关性研究[J].福建中医药大学学报,2012,22(6):1-3.[15]㊀许惠娟,谢丽华,李生强,等.绝经后骨质疏松症肾阳虚证的关联基因LTBP1mRNA的表达研究[J].中国骨质疏松杂志,2014,20(5):476-480.[16]㊀李生强,许惠娟,陈娟,等.绝经后骨质疏松症肾阴虚证关联LincRNA uc431+的表达研究[J].中国骨质疏松杂志,2016,22(8):966-971.[17]㊀许惠娟,李生强,谢丽华,等.绝经后妇女骨质疏松症肾阴虚证与免疫关联基因LRG1㊁SRC mRNA表达的相关性[J].中华中医药杂志,2017,32(3):1347-1350.[18]㊀陈娟,谢丽华,李生强,等.绝经后骨质疏松症肾阴虚证关联基因CLCF1mRNA的表达研究[J].中国骨质疏松杂志,2014,20(6):618-622.[19]㊀陈娟,谢丽华,李生强,等.lncRNA在绝经后骨质疏松症肾阴虚证中的表达特征及调控网络分析[J].中国骨质疏松杂志,2015,21(5):553-559.[20]㊀李颖,黄宏兴,吴伙燕,等.线粒体DNA相关因子与骨质疏松症中医证型的关系研究[J].广州中医药大学学报,2015,32(4):656-660.[21]㊀李生强,冯尔宥,张怡元,等.原发性骨质疏松症肾阴虚证骨组织基因表达谱研究[J].中国骨质疏松杂志,2013,19(12):1215-1218.[22]㊀李生强,冯尔宥,谢冰颖,等.原发性骨质疏松症肾阳虚证骨组织全基因表达谱研究[J].中国骨质疏松杂志,2017,23(7):843-850.[23]㊀SUO T,WANG H,LI Z.Application of Proteomics in Researchon Traditional Chinese Medicine[J].Expert Rev Proteomics,2016,13(9):871-873.[24]㊀顾炜峰.蛋白质组学技术及其临床应用研究[J].中国医药导报,2009,6(16):5-8.[25]㊀宋明,陈家旭,刘玥芸,等.论蛋白质组学与中医证候研究[J].中华中医药杂志,2017,32(11):4804-4807. [26]㊀许惠娟,陈娟,谢丽华,等.绝经后妇女骨质疏松症肾阳虚证的关联蛋白LTBP1的表达及其cDNA测序的研究[J].中国骨质疏松杂志,2015,21(8):905-909.[27]㊀谢丽华,陈娟,许惠娟,等.绝经后骨质疏松症肾阴虚证差异表达基因CLCF1蛋白表达研究[J].中国骨质疏松杂志,2015,21(12):1425-1428.[28]㊀许惠娟,陈娟,李生强,等.绝经后妇女骨质疏松症肾阴虚证的免疫蛋白相关研究[J].中国骨质疏松杂志,2016,22(12):1509-1512.[29]㊀王蕾,谢智惠,袁春生,等.骨质疏松症患者破骨细胞相关细胞因子与中医证型的关系[J].南京中医药大学学报,2017,33(2):122-124.[30]㊀邓洋洋,孙鑫,李佳,等.去卵巢骨质疏松症模型大鼠股骨㊁肾㊁下丘脑中Smurf1信号转导蛋白的活性变化研究[J].中华中医药杂志,2014,29(2):574-578.[31]㊀章建华,邢婧,范连霞,等.骨质疏松肾阳虚和肾阴虚证型下左归丸含药血清干预成骨细胞ERK1/2,Wnt/β-catenin信号通路的研究[J].中国中药杂志,2017,42(20):3983-3989.[32]㊀章建华,邢婧,范连霞,等.骨质疏松肾阳虚㊁肾阴虚证型下右归丸含药血清对大鼠成骨细胞ERK1/2㊁Wnt/β-catenin信号通路的研究[J].中华中医药杂志,2018,33(7):3018-3022.[33]㊀伍超,韦佳慧,陈涵,等.补肾益精中药治疗肾精亏虚证相关疾病的生物学物质基础及作用机制的预测与验证[J].药学学报,2020,55(3):463-472.[34]㊀秦玮,纪峰,林莺,等.电针命门穴对去卵巢骨质疏松大鼠下丘脑骨形成蛋白BMP-2及其信号转导蛋白Smad1/5表达的影响[J].时珍国医国药,2016,27(6):1530-1532. [35]㊀BEGER RD,SUN J,SCHNACKENBERG LK.Metabolomicsapproaches for discovering biomarkers of drug-inducedhepatotoxicity and nephrotoxicity[J].Toxicology&AppliedPharmacology,2010,243(2):154-166.[36]㊀王娟,谢世平.中医证候的代谢组学研究现状[J].中医学报,2013,28(8):1148-1150.[37]㊀LV H,JIANG F,GUAN D,et al.Metabolomics and ItsApplication in the Development of Discovering Biomarkers forOsteoporosis Research[J].Int J Mol Sci,2016,17(12):2018.[38]㊀徐琬梨,李肖飞,田琪.基于代谢组学的绝经后骨质疏松症实性证素研究[J].辽宁中医杂志,2020,47(3):97-101. [39]㊀张波,杨传东,史耀勋,等.骨质疏松症(肾虚血瘀证)与骨吸收标志物的相关性研究[J].中国医药指南,2013,11(7):279-280.[40]㊀帅波,沈霖,杨艳萍,等.原发性骨质疏松症 本痿标痹 的核心病机研究[J].中国中医骨伤科杂志,2015,23(5):9-12.[41]㊀姜俊杰,刘玉庆,于洋,等.基于文献计量方法的表观遗传学在中医证候本质研究中的应用[J].中医药导报,2020,26(5):83-87.[42]㊀WANG P,CHEN Z.Traditional Chinese medicine ZHENG andOMICS convergence:a systems approach to post-genomicsmedicine in a global world[J].Journal of Integrative Biology,2013,17(9):451-459.[43]㊀MA T,TAN C,ZHANG H,et al.Bridging the gap betweentraditional Chinese medicine and systems biology:the connectionof Cold Syndrome and NEI network[J].Molecular Biosystems,2010,6(4):613-619.[44]㊀孙安会,袁肇凯,夏世靖,等.中医证候系统生物学研究的现状和展望[J].中华中医药杂志,2016,31(1):200-204. [45]㊀潘志强,方肇勤.中医证候本质研究现状及引入系统生物学技术新趋势[J].中国中医药信息杂志,2009,16(1):104-107.[46]㊀翟兴,韩爱庆,张文婷,等.我国中医药系统生物学研究文献计量学分析[J].中国中医药信息杂志,2014,21(4):13-16 [47]㊀WANG X,ZHANG A,SUN H,et al.Systems biologytechnologies enable personalized traditional Chinese medicine:asystematic review[J].American Journal of Chinese Medicine,2012,40(6):1109-1122.收稿日期:2020-06-142021年‘中国中医基础医学杂志“征订启事㊀㊀‘中国中医基础医学杂志“是由国家中医药管理局主管,中国中医科学院中医基础理论研究所主办的学术性期刊㊂本刊于1995年元月创刊㊂本刊为中文核心期刊㊃中国医学类核心期刊㊂已为中国科学引文数据库㊁中国学术期刊光盘版㊁中国生物学文摘和文献㊁中文科技期刊等数据库收录㊂从2020年1期开始本刊发表的论文已被中国知网㊁超星㊁维普网㊁万方数据 数字化期刊群全文收录㊂本刊设有理论探讨㊁实验研究㊁临床基础㊁针刺研究㊁方药研究㊁中医多学科研究㊁综述等栏目,适于中医及中西医结合科研㊁临床㊁教学人员阅读㊂本刊官网㊂若想获得更多信息,可通过微信公众号搜索 中国中医基础医学杂志 进行关注㊂国内刊号:CN11-3554/R;国际刊号:ISSN1006-3250㊂本刊为月刊,每月28日出版㊂版面大16开,正文144页㊂每册定价15元㊂国内各地邮局均可订阅,国内邮发代号为:80-330;国外邮发代号为:M-4690,中国国际图书贸易集团有限公司(北京399信箱)订阅㊂。
acta biomaterialia的文献格式

acta biomaterialia的文献格式【最新版】目录1.引言2.Acta Biomaterialia 的概述3.Acta Biomaterialia 的文献格式要求4.具体的文献格式5.结论正文1.引言Acta Biomaterialia 是一本国际性的学术期刊,主要关注生物材料科学及其在医学、牙科、工程和纳米技术等领域的应用。
该期刊接收的研究论文、综述文章和通讯稿都必须遵循一定的文献格式要求。
本文将对Acta Biomaterialia 的文献格式进行详细介绍,以帮助作者准确地编写和提交论文。
2.Acta Biomaterialia 的概述Acta Biomaterialia 创刊于 2005 年,由 Elsevier 出版社出版。
该期刊主要关注生物材料科学的基础研究和应用研究,包括生物相容性、生物降解性、生物活性、组织工程、药物传递、纳米技术等方面的研究。
Acta Biomaterialia 是生物材料领域的重要学术交流平台,为全球范围内的研究人员提供了一个展示研究成果和交流学术观点的机会。
3.Acta Biomaterialia 的文献格式要求Acta Biomaterialia 对投稿的论文格式有一定的要求,包括字体、字号、行距、页边距等方面。
具体要求如下:- 字体:Times New Roman。
- 字号:12 磅。
- 行距:单倍行距。
- 页边距:2.54 厘米(1 英寸)。
此外,Acta Biomaterialia 还要求论文的标题、作者、单位、摘要、关键词等部分必须按照规定的格式书写。
具体要求可参考期刊官方网站的“作者投稿指南”。
4.具体的文献格式以下是 Acta Biomaterialia 文献格式的具体示例:- 标题:标题应简洁明了,能够准确反映论文的主要内容。
标题中的每个单词的首字母应大写,除专有名词和缩写外。
例如:The effect of surface modification on the cellular response of biomaterials。
珍稀植物日本荚蒾遗传多样性的ISSR分析

浙江大学学报(理学版)Journal of Zhejiang University (Science Edition )http :///sci第48卷第1期2021年1月Vol.48No.1Jan.2021珍稀植物日本荚蒾遗传多样性的ISSR 分析蒋明,应梦豪,徐丽娜,马佳莹,邬张颖,杨如棉,朱欣,李彦蓉(台州学院生命科学学院,浙江椒江318000)摘要:日本荚蒾是浙江省重点保护野生植物,种群数量极为稀少,仅零星分布于部分海岛。
在野外调查的基础上,对8个居群共125份日本荚蒾样品进行了ISSR 遗传多样性分析。
从100条ISSR 通用引物中筛选出7条引物用于ISSR -PCR ,共扩增得到240个谱带,其中多态性谱带232个。
在物种水平上,日本荚蒾的多态性位点百分比(PPB )达96.67%,Nei ’s 基因多样性指数(H )为0.2273,Shannon ’s 信息指数(I )为0.3581,具有较高的遗传多样性;在居群水平上,日本荚蒾的PPB 为32.61%,H 为0.0731~0.1363,均值为0.1088;I 为0.1092~0.2051,均值为0.1642;居群间基因分化系数(Gst )为0.5271,基因流(Nm )为0.4487,遗传距离为0.0982~0.2540;聚类分析结果表明,同一地理来源的日本荚蒾大多聚为一类,呈一定的地域分布规律。
日本荚蒾遗传多样性水平高,但主要存在于居群间,岛屿之间的地理隔离可能是遗传分化的主要原因。
关键词:日本荚蒾;ISSR ;珍稀濒危植物;遗传多样性中图分类号:Q 948文献标志码:A文章编号:1008⁃9497(2021)01⁃100⁃07JIANG Ming,YING Menghao,XU Lina,MA Jiaying,WU Zhangying,YANG Rumian,ZHU Xin,LI Yanrong (College of Life Sciences ,Taizhou University ,Jiaojiang 318000,Zhejiang Province ,China )The genetic diversity assessment of a rare plant Viburnum japonicum by ISSR .Journal of Zhejiang University(Science Edition),2021,48(1):100⁃106Abstract :Viburnum japonicum is listed as a key protected wild plant species in Zhejiang province,and it distributes sporadically in a few islands with extremely small populations.In this study,the genetic diversity assessment of V.japonicum was performed by ISSR using 125plants from eight populations based on field investigation.Seven primers were screened from 100ISSR universal primers,and a total of 240bands were amplified,of which 232were polymorphic.It was found that at the species level,there is a high genetic diversity in V.japonicum with a percentage of polymorphic bands (PPB)of 96.67%,and the Nei's genetic diversity index (H )and Shannon's information index (I )were 0.2273and 0.3581,respectively.At the population level,its PPB was 32.61%,and H index ranged from 0.0731to 0.1363with an average value of 0.1088,while I index varied from 0.1092to 0.2051with an average index of 0.1642.The genetic differentiation coefficient (Gst )was estimated as 0.5271,and the gene flow (Nm )was 0.4487.The genetic distances ranged from 0.0982to 0.2540,and the plant materials of V.japonicum from the same island clustered together to form monophyletic groups,suggesting discrete geographical segregation.The results show a high genetic diversity in V.japonicum ,and it manifested between populations,indicating geographical isolation of the islands is the possible cause of genetic differentation.Key Words :Viburnum japonicum ;ISSR;rare and endangered plant;genetic diversity荚蒾属(Viburnum )隶属忍冬科(Caprifoliaceae ),为灌木或小乔木,落叶或常绿。
具有总能耗约束的柔性作业车间调度问题研究

第44卷第11期自动化学报Vol.44,No.11 2018年11月ACTA AUTOMATICA SINICA November,2018具有总能耗约束的柔性作业车间调度问题研究雷德明1,2杨冬婧1摘要针对具有总能耗约束的柔性作业车间调度问题(Flexible job shop scheduling problem,FJSP),提出一种基于帝国竞争算法(Imperialist competitive algorithm,ICA)和变邻域搜索(Variable neighborhood search,VNS)的双阶段算法,该算法在总能耗不超过给定阈值的条件下最小化Makespan和总延迟时间.由于能耗约束不是总能满足且阈值往往难以事先给定,为此,第一阶段,首先,将原问题转化为具有Makespan、总延迟时间和总能耗的三目标FJSP,然后,利用初始帝国构建和帝国竞争的新策略设计一种ICA对问题求解,并根据ICA的结果确定总能耗阈值;第二阶段,应用解的比较新策略、非劣解集更新方法和当前解周期性更新,构建VNS对原问题求解.计算实验和结果分析表明,两阶段算法对于所研究的问题搜索能力强.关键词双阶段算法,总能耗约束,柔性作业车间,调度问题,帝国竞争算法,变邻域搜索引用格式雷德明,杨冬婧.具有总能耗约束的柔性作业车间调度问题研究.自动化学报,2018,44(11):2083−2091DOI10.16383/j.aas.2018.c170345Research on Flexible Job Shop Scheduling Problem With Total EnergyConsumption ConstraintLEI De-Ming1,2YANG Dong-Jing1Abstract A two-phase algorithm based on imperialist competitive algorithm(ICA)and variable neighborhood search (VNS)is proposed for theflexible job shop scheduling problem(FJSP)with total energy consumption constraint.The goal is to minimize the makespan and total tardiness under the condition that total energy consumption does not exceed a given threshold.Energy consumption constraint is not always met and a threshold is difficult to be decided in advance,so in thefirst phase,the original problem is converted into FJSP with makespan,total tardiness and total energy consumption, and an ICA is used to solve the converted problem based on some new strategies for initial empires and imperialist competition.An energy consumption threshold is obtained in terms of the results of ICA.In the second phase,a VNS is presented for the original FJSP by using new methods for comparing solutions and updating the non-dominated set and renewing current solution putational experiments are conducted and the result shows that the two-phase algorithm has strong search ability for the considered FJSP.Key words Two-phase algorithm,total energy consumption constraint,flexible job shop,scheduling problem,imperialist competitive algorithm(ICA),variable neighborhood search(VNS)Citation Lei De-Ming,Yang Dong-Jing.Research onflexible job shop scheduling problem with total energy consumption constraint.Acta Automatica Sinica,2018,44(11):2083−2091柔性作业车间调度问题(Flexible job shop scheduling problem,FJSP)广泛存在于汽车装配、纺织、化工生产和半导体制造等制造过程和行业中,收稿日期2017-06-22录用日期2017-09-07Manuscript received June22,2017;accepted September7,2017国家自然科学基金(61573264,71471151),数字制造装备与技术国家重点实验室开放课题(DMETKF2017015)资助Supported by National Natural Science Foundation of China (61573264,71471151),Open project of State Key Labora-tory of Digital Manufacturing Equipment and Technology (DMETKF2017015)本文责任编委鲁仁全Recommended by Associate Editor LU Ren-Quan1.武汉理工大学自动化学院武汉4300702.数字制造装备与技术国家重点实验室武汉4300741.School of Automation,Wuhan University of Technology, Wuhan4300702.State Key Laboratory of Digital Manufac-turing Equipment and Technology,Wuhan430074自Bruker等在1990年的开创性工作[1]之后,FJSP 的研究受到广泛关注,取得了很大进展[1−27].由于FJSP的高度复杂性,精确算法难以在合理的时间内对其求解,使得智能算法成为解决FJSP的主要手段,智能算法已成功应用于各类FJSP的求解,其中关于多目标FJSP,早期的工作为Kacem等[2]提出的基于遗传算法和局部方法的混合算法,在此之后,研究者大量应用GA(Ge-netic algorithm)[2−9]、粒子群算法[10−11]、和声搜索算法[12]、人工蜂群算法[13]、禁忌搜索[14−15]、变邻域搜索[16]、蛙跳算法[17]和分布估计算法[18]等求解FJSP.近些年,低碳制造和低碳生产调度受到工业界和学术界的广泛关注,其中关于低碳FJSP,Tang2084自动化学报44卷等[19]考虑了FJSP的能耗并运用遗传模拟退火算法求解.Liu等[20]运用GA求解双目标低碳FJSP.He等[21]提出一种节能优化算法,它通过机床选择减少机器加工能耗和操作序列调整减少机器闲置时的能源浪费.Zhang等[22]设计结合改进局部搜索的多目标GA以解决低碳FJSP.蒋增强等[23]提出了基于血缘变异的改进非劣排序遗传算法(Non-dominated sorting genetic algorithm-II, NSGA-II[28]).唐立力[24]给出一种改进型候鸟优化算法.Yin等[25]运用多目标GA解决了具有产能、能源效率和噪声减少等目标的FJSP.文献[26−27]分别利用一种新型蛙跳算法和一种新的教学优化算法求解低碳FJSP.尽管低碳FJSP的研究取得了较大进展,但其研究仍不够深入,有些问题的研究还未引起研究者的重视,例如,具有总能耗约束的FJSP,在该问题中,总能耗不是目标函数,无需最优化,总能耗只需不超过给定的阈值即可,能耗约束的加入,产生了如下几个新特征:1)总能耗约束不是总能得到满足,即智能算法的解所具有的总能耗经常超过给定的阈值.2)总能耗与机器分配和工件加工顺序密切相关,其阈值难以事先确定.3)由于以上两个特点,需要利用新原理和策略比较问题的解并更新非劣解集.如上所述,多种智能算法在FJSP和低碳FJSP 方面都具有成功的应用,不过,作为一种模拟社会政治行为的帝国竞争算法(Imperialist competitive algorithm,ICA)[29],尽管已在设备布局[30−31]、调度[32−37]、装配线平衡[38−40]、旅行商问题[41]等方面具有一些成果,但ICA较少用于FJSP和低碳FJSP的求解[36−37].根据文献[29],ICA既具有较强的邻域搜索能力,又是有效的全局优化方法,且结构灵活,这些特点表明ICA在求解FJSP和低碳FJSP方面具有不同其他算法如GA的优势,如不必像GA那样要加强局部搜索才能实现全局搜索与局部搜索的协调,因此,有必要研究ICA在FJSP 和低碳FJSP方面的应用.本文研究具有总能耗约束的FJSP,由于该问题的能耗约束经常无法得到满足,为了有效地解决问题,首先将问题转化所有约束都可满足的三目标FJSP,以简化对能耗约束的处理,同时扩大搜索区域,然后直接优化原问题,以进一步改进第一阶段的搜索结果,为此,设计基于ICA和VNS(Variable neighborhood search)的双阶段算法,先应用ICA 产生一定数量的可行解,然后运用VNS对可行解改进,其中,ICA不直接求解原问题,而是优化具有总能耗、总延迟时间和Makespan的三目标FJSP;而VNS则从第一阶段获得的解出发,对原问题求解,并通过周期性更新当前解增强VNS的探索能力和它本身较强的局部搜索能力,不断提高解的质量.通过大量仿真实验,验证所得阈值的合理性和算法的搜索性能.1问题描述具有能耗约束的FJSP描述如下:存在工件集J={J1,J2,···,J n}和机器集M={M1,M2,···,M m}.工件J i具有h i道工序,工序o ij为工件J i的第j道工序,该工序可由相容机器集S ij中的任何一台机器加工,S ij⊂M.机器M k具有两种模式:加工模式和空闲模式.E k,SE k分别表示机器M k在加工模式和空闲模式时单位时间的能耗.存在一些与机器和工件相关的约束,包括同一时刻一台机器最多只加工一道工序,同一时刻一个工件最多只能在一台机器上加工,工序加工不能中断准备时间和清理时间包含在加工时间内等.另外,还考虑总能耗约束T EC≤Q EC,式中,T EC=C maxni=1h ij=1mk=1E k y ijk(t)+mk=1SE k z k(t)d t(1)其中,T EC表示总能耗,y ijk(t)为二进制量,如果在时刻t机器M k∈S ij处于加工模式,则y ijk(t)= 1;否则,y ijk(t)=0;如果机器M k在时刻t处于空闲,则z k(t)=1;否则,z k(t)=0.Q EC为总能耗阈值.C max表示最大完成时间.问题包括调度子问题和机器分配子问题.问题的目的在于在所有约束满足的条件下同时最小化如下两个目标函数.f1=C max(2)f2=ni=1max{C i−D i,0}(3)其中,C i,D i表示工件J i的完成时间和交货期,目标函数f1,f2分别为Makespan和总延迟时间.对于多目标优化问题,假设其目标总数为G且都是最小化目标,其最优解不再只是单独一个解,而是一组解的集合,且需要通过比较所有解才能确定最优解集.通常,要用到如下几个概念:对于解x,y,如果对于∀i∈{1,2,···,G},f i(x)≤f i(y);且∃i∈{1,2,···,G},f i(x)<f i(y),则解x Pareto支配y.对于集合Φ和解x∈Φ,如果x不受集合Φ的其他任何解支配,则x关于集合Φ是非劣的.如11期雷德明等:具有总能耗约束的柔性作业车间调度问题研究2085果一个解不受问题解空间内的任何其他解支配,则该解为Pareto最优解.2求解具有总能耗约束的FJSP的双阶段算法对于所研究的FJSP,需要确定合适的能耗阈值,同时在所有约束条件满足的情况下,最优化两个目标函数,为了完成这两个任务,提出一种基于ICA和VNS的双阶段算法.2.1编码针对具有n个工件和m台机器的FJSP,通常利用调度串[(θ1,r1),(θ2,r2),···,(θi,r i),···,(θh,r h)]和机器分配串[q11,q12,···,q1h1,···,q nhn]来表示问题的一个解,其中,h=ni=1h i表示工序总数.在第一个串中,θi∈{1,2,···,n},1≤r i≤hθi ,二元组(θi,r i)对应工序oθir i,这样整个串对应一个有序工序表[oθ1r1,oθ2r2,···,oθir i,···,oθhr h].第二个串中,基因q ij∈S ij表示用于加工工序o ij 的相容机器.上述编码方法[27,41]能保证除总能耗约束T EC≤Q EC之外的其他约束总是成立,但无法保证能耗约束总是成立.对于新加入的约束T EC≤Q EC,需要确定阈值Q EC并处理不可行解.2.2第一阶段:ICA本阶段首先将能耗约束从原问题中去掉,而增加第三个目标f3=T EC,这样问题变成具有f1,f2,f3的FJSP,通过问题的转化,将原问题转化为所有约束都可以得到满足的问题;然后,设计一种新的ICA对三目标FJSP进行求解;最后,根据ICA的结果确定合适的阈值.由于原问题的不可行解是转化后问题的可行解,这样扩大了ICA的搜索区域,有助于获得高质量的解.ICA的主要步骤包括构建初始帝国、殖民地同化、殖民地革命、交换和帝国竞争,本文根据转化后的FJSP的特点,采用一些新策略实现ICA的以上步骤,构建新的ICA.由于只增加一个目标,只在第一阶段优化三目标FJSP,ICA的非劣排序复杂性将有所增加,但非劣排序不是每代都做,故问题转化对算法复杂度的影响不大.2.2.1初始帝国构建由于所研究FJSP的多目标特性,导致种群中的优秀个体经常彼此非劣,当这些个体被选作殖民国家时,应该分配相近数量的殖民地以同等对待它们.基于该思想,提出了一种初始帝国构造新方法.假设初始帝国总数为N im,种群规模为N,显然,殖民地总数N c=N−N im,其具体过程如下:步骤1.对初始种群P中的解按文献[28]的方法进行非劣排序,得到每个解的rank值.步骤2.确定rank值为1的η个解.步骤3.如果η<N im,则种群P中η个非劣解分别为帝国k=1,2,···,η的殖民国家,剩余帝国的殖民国家为种群中rank值最小的受支配解;否则,随机选择N im个非劣解,使它们成为帝国的殖民国家.步骤4.对于每个帝国k=1,2,···,N im,如果k<N im,则F k=A+u或B+u,u∈{0,1};否则F Nim=N−N im−1k=1F k;确定F k之后,为帝国随机分配F k−1个国家作为殖民地.其中,F k表示帝国内的国家总数,A,B如式(4)∼(5)所示,假设N im=6.A=round(0.3N),η=1round(0.2N),η=2round(0.2N),η=3round(0.18N),η=4round(0.18N),η=5round(N/6),η≥6(4) B=roundN−ηAN im−η,若η<N im0,其他(5)其中,round(z)为最接近z的整数.当η<N im时,存在两类初始帝国,其中第一类η个帝国的殖民国家都是种群P中的非劣解,帝国包含F k=A+u个国家;第二类N im−η个帝国的殖民国家为具有最小rank值的受支配解,这样的受支配解共有N im−η个,相应的F k=B+u.若η≥N im,则随机选择N im个非劣解作为帝国的殖民国家.显然,以上初始帝国建立过程不同于文献[42−43]中的相应过程.2.2.2同化与革命同化和革命是ICA的重要步骤,本文提出了革命的实现新途径.对于调度问题,同化往往通过利用殖民地和殖民国家之间的交叉[32−37]来实现.本文的同化过程如下:对于帝国内的殖民地λ和殖民国家v,随机产生一个随机数s,如果s<ζ,则对两个解的调度串应用第一种交叉;否则,对两个解的机器分配串应用第二种交叉,产生新解z,并与殖民地λ进行比较,若新解支配殖民地λ或者与殖民地λ彼此非劣,则利用新解替代殖民地λ,并2086自动化学报44卷更新非劣解集Ω,其中两种交叉的详细过程见文献[26−27].通常,调度子问题比机器分配子问题更复杂,求解难度更大,为此,令ζ>0.5以分配更多的计算资源给调度子问题,通过实验确定,ζ=0.6.非劣解集Ω的更新过程如下:将新解加入到集合Ω之后,对集合内的所有解进行Pareto比较,保留非劣解,剔除受支配解.以上更新过程是根据三个目标f1,f2,f3对解进行比较,而不是原问题中的f1,f2.殖民地革命模拟某种非预期的改变,例如,改变殖民地的语言或宗教,从而改变其特征和地位[29].本文采用新的策略实现殖民地革命,其具体过程描述如下:对于帝国k步骤1.令α←1,对于每个τ=1,2,···,F k,产生随机数rand,若rand<U R,则α←α+1.步骤2.根据Pareto支配对帝国内的所有殖民地进行比较,确定每个殖民地λ的wλ.步骤3.若α>1,则对于l=1,2,···,α,执行如下步骤:确定具有最小wλ的殖民地λ,令g←1重复执行如下步骤R次:若g=1,则对殖民地λ执行insert;否则,对殖民地λ执行change,产生新解z;若新解支配殖民地λ或者与殖民地λ彼此非劣,则利用新解替代殖民地λ并更新集合Ω;否则g←g+1,若g=3则g←1.其中,R为整数,U R表示革命概率.关于革命概率U R,文献[42−43]分别将其设置为0.35和0.3.与文献[42−43]不同,只有部分相对优秀的殖民地参与革命过程,基于这一特征,本文选择一个较小的U R,根据实验确定U R为0.1.对于帝国内殖民地,如果殖民地λ受同一帝国的其他wλ个殖民地支配,则该殖民地赋给值wλ.只有wλ值最小的部分殖民地参与革命,这是因为利用较优秀的殖民地更容易获得更好的殖民地,甚至产生新的殖民国家.由于FJSP具有两个子问题,为此,运用多种邻域结构insert,swap和change产生新解,其中,insert将随机选择的调度串元素(θi,r i)插入到新位置k=i并随后根据θi在调度串中出现的次序为r i重新赋值[26].swap则在互换调度串的两个不同元素之后为r i重新赋值.change的实现过程如下:首先构建集合Θ={q ij||S ij|>1, i=1,2,···,n,j=1,2,···,h i},然后从集合中随机选择一些元素,为它们重新赋值,例如,q ij被选中,则从S ij中随机确定一台机器替代当前的q ij. 2.2.3帝国竞争帝国竞争是ICA的重要步骤.对于本阶段考虑的三目标FJSP,给出了一种新方式来计算一个解的成本(cost),成本值主要根据解的rank值和拥挤距离来确定,为此,首先通过非劣排序[28]将种群分解成rank max个H l,其中,H l内元素的rank值均为l;然后,对每个集合H l的非边界解,按文献[28]的方法计算拥挤距离,得到这些距离的最大值ψ,边界解的拥挤距离为ψ+α,其中,α≥1,利用α是为了区分边界解与其他解.帝国竞争的新过程描述如下:如果N im≥2步骤1.确定种群P内所有解的rank值和拥挤距离.步骤2.对于集合H l,l=1,2,···,rank max,将该集合内解的成本定义为l+dist if∈H ldist f,其中,dist f表示个体f∈H l的拥挤距离.步骤3.按照基本ICA[29]的过程实现帝国竞争的剩余步骤.计算帝国总成本时的参数ζ仍取0.1.2.2.4ICA描述ICA的具体过程如下:步骤1.随机产生初始种群并确定初始集合Ω.步骤2.殖民地同化与革命.步骤3.殖民地与殖民国家之间的交换.步骤4.帝国竞争.步骤5.如果第一阶段的终止条件成立,则停止搜索;否则转到步骤2.其中交换过程如下:对于帝国内的每个殖民地,确定殖民地能否支配殖民国家或者与殖民国家彼此非劣,是,则利用殖民地替代当前殖民国家,成为帝国新的殖民国家,而原殖民国家则变成殖民地.第一阶段终止条件为目标函数估计次数,由于步骤2每次循环产生的解个数不一样,在步骤2执行过程中,要判断终止条件是否成立,成立则停止搜索.总之,ICA根据所研究FJSP具有多目标、双子问题和调度子问题更复杂等特点,构建初始帝国、让优秀殖民地参加革命、同化过程偏重于调度子问题的优化以及结合rank值和拥挤距离进行帝国竞争,这些策略与问题特点相适应,有助于提高ICA 的求解质量.2.2.5总能耗阈值文献[44]考虑了能耗阈值Q EC,但并未讨论如何确定阈值大小.本文根据第一阶段ICA的优化结果来确定阈值,这样可以减少决策者的认知和决策11期雷德明等:具有总能耗约束的柔性作业车间调度问题研究2087负担.关于每个实例,获得Q EC 的具体过程如下:步骤1.ICA 随机运行20次;步骤2.计算Q i =max {T EC (z )|z ∈Ωi },¯Q =12020i =1Q i ;步骤3.从所有满足Q i ≥¯Q的Q i 中剔除一些相近的Q i ;步骤4.运行两阶段算法并根据计算结果确定哪个Q i ≥¯Q可以作为Q EC .其中,Ωi 表示ICA 第i 次运行所获得的非劣解集.2.3第二阶段:VNS本阶段利用VNS 求解具有T EC ≤Q EC 的FJS-P,由于总能耗约束不总是得到满足,需要处理不可行解,为此,给出一种新原则来比较两个解x,z :1)T EC (x )>Q EC 和T EC (z )≤Q EC ;2)x,z 都是可行解,且z 不受x 支配;3)x,z 都是不可行解,且T EC (z )≤T EC (x ).以上三个条件只要有一个满足,则解x 被z 替代,其中条件(2)根据f 1,f 2对两个解进行Pareto 比较.关于集合Ω,第一阶段它由通过比较f 1,f 2,f 3而得到的非劣解组成,在从第一阶段过渡到第二阶段,该集合被直接保留下来,这样,导致Ω中存在一些不可行解.第二阶段集合Ω的更新过程如下:对于解x 1)若T EC (x )>Q EC如果集合Ω中至少存在一个不可行解y ,且满足T EC (x )<T EC (y ),则解y 被x 所替代.2)若T EC (x )≤Q EC如果集合Ω所有解都可行,则存在两种情况.a)解x 与Ω中的一个成员具有相同的f 1,f 2,但x 的总能耗更小,则利用x 替代该成员.b)情况1的条件不成立,则直接将x 添加到集合Ω中,对所有解根据f 1,f 2进行Pareto 比较,剔除所有受支配解.如果集合Ω中存在不可行解,则直接用x 替代其中一个不可行解.VNS 的详细步骤如下:步骤1.将集合Ω中的第一个解当作当前解,令w ←max it 1.步骤2.令g ←1.步骤3.重复如下步骤直到g =3或w >max it 随机产生解z ∈N g (x ).根据上述原则,如果x 能被z 所替代,则直接替代,并利用新的x 更新集合Ω且g ←1;否则,g ←g +1.如果w 能被整数β整除,则选择y ∈Ω并替代x .步骤4.如果w ≤max it ,则转到步骤2;否则,停止搜索,剔除Ω中的非可行解.其中,max it 1为第一阶段的终止条件,max it 为整个两阶段算法的终止条件,N 1,N 2,N 3分别表示邻域结构swap ,insert ,change ,N g (x )表示运用N g 所产生的x 的邻域解集.集合Ω更新过程中,每次最多只剔除一个非可行解,是为了使Ω中保留足够多的解,以便在重新选择当前解时有更多的可能性.2.4算法描述:两阶段算法如上所述,运用两阶段算法可以简化对能耗约束的处理,扩大ICA 的搜索区域,从而提高搜索质量.另外,它还具有如下特点:它不仅能求解所考虑的FJSP,而且能获得合适的总能耗阈值;它将全局搜索算法和局部搜索算法有机地结合在一起.3计算实验为了测试两阶段算法在求解具有总能耗约束的FJSP 方面的性能,利用37个实例MK1-15[45]、DP1-18[46]、Ka4×5、Ka10×7、Ka10×10、Ka15×10[2]进行计算实验,这些实验由Microsoft Visual C++6.0编程实现,并运行于4.0GB RAM 1.70GHz CPU PC.为了用于所研究的FJSP,在37个实例中引入能耗信息:E k ∈[2,4],SE k =1,其交货期计算公式如下:D i =δh ij =1max k =1,2,···,m{p ijk }(6)其中,δ的值如表1所示.表1δ的设置Table 1The setting on δδInstances δInstances [0.5,0.7]MK01,MK03-05[1.0,1.5]DP1-12[0.3,0.5]MK02,06,08-10[1.2,1.6]MK11-15[0,1,0.3]Ka4×5,10×7,15×10[0.7,0.9]MK07[1.2,1.7]DP13-18[0.05,0.2]Ka10×10采用指标DI [47]R 评价算法的收敛性能,它为非劣解集Ωl 与参考集Ω∗之间的距离,如式(7)所示.DI R (Ωl )=1|Ω∗|y ∈Ω∗min {σxy |x ∈Ωl }(7)2088自动化学报44卷其中,σxy表示解x与参考解y在归一化目标空间中的距离,σxy=(f∗1(x)−f∗1(y))2+···+(f∗G(x)−f∗G(y))2f∗i 为第i个归一化目标,参考集Ω∗由并集lΩl中的非劣解组成.指标ρ[48]l等于集合{x∈Ωl|x∈Ω∗}的大小与|Ω∗|的比值.比值越大,说明Ωl为参考集Ω∗提供的非劣解越多.选用NSGA-II[8]和VNS[16]作为对比算法,这两种算法对FJSP具有较多的应用[5,8,16,23],且很容易应用于所研究的FJSP的求解.NSGA-II作为求解多目标优化问题的著名算法,其主要步骤包括非劣排序和拥挤距离的计算等.文献[8]针对具有随机故障的FJSP,应用NSGA-II求解,为了应用于具有总能耗约束的FJSP,对该算法做如下修改:去掉与随机故障相关的部分,对可行解采用算法原来的非劣排序和拥挤距离计算,所有不可行解赋予同样的且大于可行解最大rank值的rank值,拥挤距离设置为ωmax−T EC(x),其中,ωmax为足够大的正数.文献[16]所设计的VNS用来解决具有加权目标的FJSP,将第2.3节中新旧解更替原则和非劣解集更新策略引入后,该VNS可直接求解本文所研究的FJSP,但该VNS与两阶段算法中的VNS的邻域结构和算法结构不一样.两阶段算法的参数设置如下:N=80,N im= 6,max it1=20000,max it关于Ka4×5为2.5×104,关于其他实例为105,β关于Ka4×5为4000,关于其他实例为5000,R=8.NSGA-II的参数如下:种群规模为100,交叉概率为0.8,变异概率为0.1,最大代数为max it/100.这些参数值根据计算实验而得,是使算法获得最佳结果的一组值.关于VNS,n max=350由文献[16]给出, max it与两阶段算法相同.关于总能耗阈值Q EC,如果阈值过大,大多数解都满足总能耗约束,这样的阈值没有意义;如果阈值过小,则算法很难得到可行解,导致整个算法的优化只是处理能耗约束,目标函数难以得到充分的优化,故需要设置一个合适的阈值.第2.2节给出了确定阈值的详细过程,以Ka10×7为例,随机运行ICA20次,得到20个Q i,如表2所示,¯Q等于229.7;然后,对于大于¯Q的Q i,剔除230.2,232.4,244.4,254.1等相近的值,得到剩余的Q i;最后,运行整个两阶段算法,分别测试剩余的Q i,根据上述两种指标评价计算结果,最终确定245.9作为阈值.表2阈值的确定Table2Decision on threshold所有Q i大于¯Q的Q i剩余的Q i 216.7,198.9,227.3,218.0230.2,231.6231.6,245.9230.2,224.6,231.6,244.4244.4,237.7237.7218.9,208.2,237.7,221.4253.4,245.9253.4223.1,253.4,245.9,232.4232.4,254.1232.4207.6,254.1,284.1,216.4284.1284.1由于阈值是ICA进化的结果,同时又大于¯Q,故阈值大小合适.表3给出了关于各个实例的阈值以及三种算法最终所获得的非劣解所对应的实际能耗,其中ATEC和MTEC表示非劣解集中所有非劣解的最小能耗值和平均能耗值.如表3所示,三种算法关于所有实例所得到的ATEC和MTEC都小于Q EC,而且关于大多数实例这两个指标都与Q EC接近,这说明第二阶段总能耗的下降速度显著降低了,从而说明第二阶段的新旧解更替原则和集合的更新策略是合理的,第二阶段主要用于目标函数f1,f2的最小化处理.表4和5描述了三种算法的计算结果和计算时间,可以看出,两阶段算法关于几乎所有实例所产生的结果明显由于另外两种算法.两阶段算法关于19个实例提供了参考集的所有元素,而NSGA-II和VNS关于这19个实例所获得的解都受两阶段算法的非劣解支配,NSGA-II只是关于Ka10×7产生了参考集的全部成员,MK06的参考集全部都由VNS 提供,另外,NSGA-II和VNS搜索所得的解总是距参考集较远,总之,两阶段算法利用和另外两种算法相似的计算时间取得了明显占优的计算结果.表3总能耗阈值和三种算法的ATEC和MTEC Table3Total energy consumption threshold and ATEC and MTEC of three algorithmsInstance Q EC两阶段算法NSGA-II VNSATEC MTEC ATEC MTEC ATEC MTEC Ka4×5152.396.15495.25996.08095.25995.25995.259 Ka10×7245.9196.27185.41194.39193.26200.52193.50 Ka10×10159.5124.81121.26130.29128.24132.17124.26 Ka15×10443.3313.85302.87325.01321.45365.49354.56 MK01682.4653.38650.79666.54664.84655.55654.41 MK02550.7509.51496.17525.17519.14508.72506.36 MK0335973148.63128.23311.53291.13278.43235.5 MK0411911083.41064.41097.51078.41086.41074.9 MK0527482628.12619.82588.02578.72648.42631.6 MK0623492162.82145.92189.42168.52127.02106.3 MK0717281504.21486.01567.61561.11524.61517.7 MK0810*******.49713.1100049976.49747.89747.8 MK0990828627.08604.98996.08961.38622.38572.311期雷德明等:具有总能耗约束的柔性作业车间调度问题研究2089Instance Q EC两阶段算法NSGA-II VNS ATEC MTEC ATEC MTEC ATEC MTECMK1097288537.18536.28991.68955.69022.78972.6 MK1112890124151227612640125771241712353 MK1214933142911422014314141481421414109 MK1314202131311310413845137631338213310 MK1416985149161485615307152391502014981 MK1517000137931365613877137861364313612 DP134534338293374534117340263390233758 DP240332385743839438874388133865438512 DP336428352713508635701355043536735215 DP436880361713565636077357423622536089 DP540085388153876639428392523888238619 DP637091358823572936445361623618535897 DP726373606676054261033609896070760673 DP852422499484987050638506275072250527 DP964539623956223263458632026328262966 DP1060350585805813359242591455927759070 DP1157613555485537356332562605611855612 DP1260711580225798159288589475826058220 DP1386142843828433585046850278520085062 DP1483000809408080382332821358188981787 DP1573000709777063172033718547180071702 DP1680468787907858479976798787941779266 DP1786677848868479885963856758539485324 DP1886330841148368584951847858504584679表4三种算法的计算结果Table4Computational results of three algorithmsInstanceDI Rρl两阶段算法NSGA-II VNS两阶段算法NSGA-II VNSKa4×5 1.2350.890 1.1250.3070.2220.370 Ka10×715.100.00020.650.000 1.0000.000 Ka10×100.0040.340.0860.9690.0000.031 Ka15×100.2569.45635.880.8890.1110.000 MK010.44661217.3050.6940.0000.306 MK020.0037319.326 1.0000.000.00 MK030.00051.9030.71 1.0000.000.00 MK042763293016520.6000.1500.250 MK05 3.11959.047.0240.6670.0000.333 MK0618.1545.790.000.000.00 1.000 MK070.00031.499.899 1.0000.000.00 MK080.00025.0410.86 1.0000.000.00 MK090.00049.7610.23 1.0000.000.00 MK100.00038.2418.00 1.0000.000.00 MK1113.42326513250.5880.0000.412 MK120.0037011542 1.0000.000.00 MK130.00064.4032.30 1.0000.000.00 MK140.00060.0423.99 1.0000.000.00 MK150.29739.9919.860.9440.0000.056 DP10.0025281324 1.0000.000.00 DP27.50739.16 4.6630.5500.0000.45InstanceDI Rρl两阶段算法NSGA-II VNS两阶段算法NSGA-II VNS DP3 1.42437.62 5.6380.9150.0000.085 DP41427291173020.7500.0000.250 DP5 5.86150.89 4.4520.5830.0000.417 DP60.00052.1612.64 1.0000.000.00 DP70.00033.5319.41 1.0000.000.00 DP80.65242.320.470.9880.0000.012 DP90.00066.4334.33 1.0000.000.00 DP100.543483611.200.9500.0000.050 DP110.00034.2114.03 1.0000.000.00 DP12 2.59767.65 4.8140.6670.0000.333 DP130.00332620.31 1.0000.000.00 DP140.25846.0812640.9810.0000.019 DP150.00046.2019.04 1.0000.000.00 DP160.00067.3444.41 1.0000.000.00 DP170.00034.6916.09 1.0000.000.00 DP180.00039.6421.59 1.0000.000.00表5三种算法的计算时间Table5Comparisons on the computational times ofthree algorithmsInstanceRunning time(s)InstanceRunning time(s)两阶段NSGA-II VNS两阶段NSGA-II VNS 算法算法Ka4×50.6880.6660.272DP110.7410.8513.03 Ka10×7 1.901 3.341 1.795DP212.9111.3514.52 Ka10×101.879 3.323 1.984DP311.5910.9614.67 Ka15×103.339 4.337 3.417DP411.8311.4911.76 MK01 2.791 4.068 3.136DP511.2110.9411.73 MK02 2.799 4.037 3.358DP610.8411.1811.47 MK037.3517.5958.498DP718.3318.0919.68 MK04 4.110 5.141 4.895DP818.2617.4619.84 MK05 6.740 5.335 6.600DP917.0217.8018.79 MK067.654 6.0377.419DP1018.7317.8420.16 MK07 5.238 6.072 5.325DP1117.5818.0219.78 MK0814.1813.9815.31DP1217.7517.9219.82 MK0912.5414.8414.87DP1331.5431.9428.87 MK1012.5113.1614.82DP1430.2432.1427.82 MK1112.2912.2712.39DP1529.4131.7028.97 MK1212.8413.4414.93DP1631.7433.5627.42 MK1313.2013.6215.08DP1731.1341.8428.07 MK1416.6316.7718.95DP1829.3832.9628.71 MK1516.1416.6018.65两阶段算法的优良性能主要来自于算法的两阶段结构以及全局搜索和局部搜索的良好协调,而ICA和VNS的一些改进策略进一步增强了算法性能,因此,两阶段算法是解决具有总能耗约束的FJSP具有较强竞争力的方法.2090自动化学报44卷4结论尽管FJSP已得到较充分的研究,但具有总能耗约束的多目标FJSP的研究相对较少,随着绿色制造和低碳制造的应用不断深入,需要进一步研究节能FJSP.本文提出一种基于ICA和VNS的两阶段算法在总能耗不超过给定的阈值条件下最小化Makespan和总延迟时间.第一阶段将原问题转化为包括总能耗的三目标FJSP,然后利用新策略构建ICA以优化转化后的FJSP,并根据第一阶段的结果确定总能耗阈值;第二阶段则运用一种高效的VNS 对原问题求解.计算结果表明,两阶段算法具有较强的搜索性能和优势.未来我们将继续深入研究具有总能耗或峰值能耗约束的调度问题,并进一步研究帝国竞争算法在低碳生产调度方面的应用;另外,分布式调度也是我们未来研究的主题之一.References1Brucker R,Schlie R.Job-shop scheduling with multi-purpose puting,1990,45(4):369−3752Kacem I,Hammadi S,Borne P.Pareto-optimality approach forflexible job-shop scheduling problems:hybridization of evolutionary algorithms and fuzzy logic.Mathematics and Computers in Simulation,2002,60(3−5):245−2763Gao J,Gen M,Sun L Y,Zhao X H.A hybrid of genetic algorithm and bottleneck shifting for multiobjectiveflexi-ble job shop scheduling puters&Industrial Engineering,2007,53(1):149−1624Chiang T C,Lin H J.A simple and effective evolutionary algorithm for multiobjectiveflexible job shop scheduling.In-ternational Journal of Production Economics,2013,141(1): 87−985Yuan Y,Xu H.Multiobjectiveflexible job shop scheduling using memetic algorithms.IEEE Transaction on Automa-tion Science&Engineering,2015,12(1):336−3536Rohaninejad M,Kheirkhah A,Fattahi P,Vahedi-NouriB.A hybrid multi-objective genetic algorithm based onthe ELECTRE method for a capacitatedflexible job shop scheduling problem.The International Journal of Advanced Manufacturing Technology,2015,77(1−4):51−667Li J Y,Huang Y,Niu X W.A branch population genetic algorithm for dual-resource constrained job shop scheduling puters&Industrial Engineering,2016,102: 113−1318Ahmadi E,Zandieh M,Farrokh M,Emami S M.A multi ob-jective optimization approach forflexible job shop schedul-ing problem under random machine breakdown by evo-lutionary puters&Operations Research, 2016,73:56−669Shen X N,Han Y,Fu J Z.Robustness measures and ro-bust scheduling for multi-objective stochasticflexible job shop scheduling problems.Soft Computing,2017,21(21): 6531−655410Rohaninejad M,Sahraeian R,Nouri B V.Multi-objective optimization of integrated lot-sizing and scheduling problem inflexible job shops.RAIRO-Operations Research,2015, 50(3):587−60911Singh M R,Singh M,Mahapatra S S,Jagadev N.Par-ticle swarm optimization algorithm embedded with maxi-mum deviation theory for solving multi-objectiveflexible job shop scheduling problem.International Journal of Advanced Manufacturing Technology,2016,85(9−12):2353−2366 12Gao K Z,Suganthan P N,Pan Q K,Chua T J,Cai T X, Chong C S.Pareto-based grouping discrete harmony search algorithm for multi-objectiveflexible job shop scheduling.Information Sciences,2014,289:76−9013Li J Q,Pan Q K,Tasgetiren M F.A discrete artificial bee colony algorithm for the multi-objectiveflexible job-shop scheduling problem with maintenance activities.Ap-plied Mathematical Modelling,2014,38(3):1111−113214Li J Q,Pan Q K,Suganthan P N,Chua T J.A hybrid tabu search algorithm with an efficient neighborhood struc-ture for theflexible job shop scheduling problem.Inter-national Journal of Advanced Manufacturing Technology, 2011,52(5−8):683−69815Jia S,Hu Z H.Path-relinking tabu search for the multi-objectiveflexible job shop scheduling puters &Operations Research,2014,47:11−2616Bagheri A,Zandieh M.Bi-criteriaflexible job-shop schedul-ing with sequence-dependent setup times-variable neighbor-hood search approach.Journal of Manufacturing Systems, 2011,30(1):8−1517Li J Q,Pan Q K,Xie S X.An effective shuffled frog-leaping algorithm for multi-objectiveflexible job shop scheduling problems.Applied Mathematics and Computation,2012, 218(18):9353−937118Wang L,Wang S Y,Liu M.A Pareto-based estimation of distribution algorithm for the multi-objectiveflexible job-shop scheduling problem.International Journal of Produc-tion Research,2013,51(12):3574−359219Tang D B,Dai M.Energy-efficient approach to minimizing the energy consumption in an extended job-shop scheduling problem.Chinese Journal of Mechanical Engineering,2015, 28(5):1048−105520Liu Y,Tiwari A.An investigation into minimising total en-ergy consumption and total completion time in aflexible job shop for recycling carbonfiber reinforced polymer.Procedia CIRP,2015,29:722−72721He Y,Li Y F,Wu T,Sutherland J W.An energy-responsive optimization method for machine tool selection and opera-tion sequence inflexible machining job shops.Journal of Cleaner Production,2015,87:245−25422Zhang R,Chiong R.Solving the energy-efficient job shop scheduling problem:a multi-objective genetic algorithm with enhanced local search for minimizing the total weighted tardiness and total energy consumption.Journal of Cleaner Production,2016,112:3361−337523Jiang Zeng-Qiang,Zuo Le.Multi-objectiveflexible job-shop scheduling based on low-carbon puter Inte-grated Manufacturing Systems,2015,21(4):1023−1031(蒋增强,左乐.低碳策略下的多目标柔性作业车间调度.计算机集成制造系统,2015,21(4):1023−1031)24Tang Li-Li.Improved migrating birds optimization algo-rithm to solve low-carbon scheduling puter Engineering and Applications,2016,52(17):166−171(唐立力.求解低碳调度问题的改进型候鸟优化算法.计算机工程与应用,2016,52(17):166−171)25Yin L J,Li X Y,Gao L,Lu C,Zhang Z.A novel mathemat-ical model and multi-objective method for the low-carbon flexible job shop scheduling problem.Sustainable Comput-ing:Informatics and Systems,2017,13:15−30。
造血干细胞移植治疗自身免疫病

ReviewWill hematopoietic stem cell transplantation curehuman autoimmune diseases?Alberto M.MarmontII Division of Hematology and Stem Cell Transplantation Center,Azienda Ospedaliera-Universitaria S.Martino,Genova,ItalyAbstractHematopoietic stem cell transplantation is becoming an accepted therapy for severe autoimmune diseases,and over 1000patients have been transplanted worldwide.Diseases include neurological (multiple sclerosis,others),rheumatological (systemic sclerosis,systemic lupus erythe-matosus,rheumatoid arthritis,vasculitis),haematological (aplastic anemia,single line immune mediated cytopenias)and others.The aim of this article is not to review the copious specific literature,but to analyze whether the up to now existing evidence satisfies the requirements of cure.Prospective randomized trials have been launched by the European Group of Blood and Marrow Transplantation (EBMT).Autologous transplantation,by far the most widely utilized because of its safety,has been shown to possess a powerful disease-arresting effect,but whether the attendant immune reconstitution (‘‘re-education’’)will finally lead to cure is not demonstrated.The experience with al-logeneic transplantation is too limited to draw even tentative conclusions.A Graft-versus-Autoimmunity effect has been ascertained both exper-imentally and clinically,but cure of autoimmunity by this procedure has not been demonstrated.Unexpected relapses in spite of full donor chimerism have been published.Further experience and studies are necessary.Ó2007Elsevier Ltd.All rights reserved.Keywords:Stem cell transplantation;Autoimmune diseases1.IntroductionAutoimmune diseases (ADs)can strike any body compo-nent,and estimates suggest that from 3to 8%of people in de-veloped countries are affected.Over 60well-credentialled entities are discussed in Rose and Mackay’s recent,authorita-tive volume [1].Definition is inspired by the 1993Rose and Bona’s criteria [2],to which the transfer of an AD by stem cell transplantation (SCT)has been added [3].While the ma-jority of ADs will respond to the array of current and novel therapies [4],two key problems must be addressed:the exis-tence of severe,constantly relapsing,progressively refractory ADs,not seldom worsened by adverse therapeutic effects,and the persistent difficulty to achieve a cure,that is obtaining the Holy Grail of tolerance [5,6].2.History and rationaleTwo streams of research are the origin of the increasing uti-lization of stem cell transplantation (SCT)for severe autoim-mune diseases (SADs;[7]):one experimental and the other clinical.The latter divided itself further in the allogeneic and autologous branches.The first of these came originated from serendipitous observations of patients having undergone SCT (generally BMT)because of coincidental diseases [8],but has not attained a widespread utilization,as will be discussed later.The second has grown steadily,the literature is copious,two monographic writings have been published [9,10],and the latest review article has appeared in 2007[11].However all the clinical area would not have developed without the power-ful impulse of experimental studies,which provided a bridge for studies in humans.As described in detail elsewhere [12],following the murine lupus transfer experiments the pivotal cells were shown to be stem or lymphoid progenitors [13,14].The next step was,ofE-mail address:alberto.marmont@hsanmartino.it0896-8411/$-see front matter Ó2007Elsevier Ltd.All rights reserved.doi:10.1016/j.jaut.2007.12.009Journal of Autoimmunity 30(2008)145e150course,to cure animal ADs utilizing hematopoietic stem cells (HSC)from not affected congeners,as most extensively per-formed by the Osaka group[15].Also human blood SC were shown to be capable of suppressing antibody production in lupus mice[16],perhaps thefirst demonstration of a curative effect by xenogeneic SCT.Further recent improvements,al-ways in experimental animals,have been the perfusion of the marrow source in order to avoid contamination with circu-lating T cells[17],and the intra-bone injection of the same [18,19],which had beenfirst utilized for the treatment of ex-perimental ADs[20],and is now being transferred to the clinic [20,21].The resolution of experimental ADs by means of healthy, compatible allo-SCT was to be expected,considering the over-whelming genetic predisposition of inbred strains of mice[22], differently from the complexity of human ADs,where there is a still poorly understood relationship between genetic,environ-mental and regulatory factors[23].An unexpected conceptual revolution took place with the studies of van Bekkum and hisgroup[24],who were able to cure experimental autoimmune en-cephalomyelitis(EAE)and adjuvant arthritis(AA),two models of human multiple sclerosis(MS)and rheumatoid arthritis (RA),by means of autologous(‘‘pseudoautologous’’)HSCT. The explanation of these unexpected results was indicated in the distinction between antigen-induced ADs such as those uti-lized in these experiments,and spontaneous ADs,which have been considered by Ikehara as polyclonal stem cell diseases [25].Only thefirst category is amenable to a cure by means of AHSCT.Nevertheless,these apparently paradoxical results considerably strengthened the philosophy of autologous HSCT for human ADs,which has grown so impressively in the decade following thefirst transplant in clinical SLE[26].Clinical observations were soon to follow.Besides the transfer of an AD from a HSC donor to a recipient following SCT(a typical example of adoptive autoimmunity,which must be distinguished from the development of a secondary AD [27]),a series of patients with coincidental diseases went into complete,long-term remission of both diseases following allo-BMT[7].More detailed information is published else-where[6,28].3.Autologous hematopoietic stem cell transplantationThe utilization of AHSCT for SAD has enormously ex-panded in the last decade.In the latest survey by the Working Party of the European Group for Blood and Marrow Transplan-tation(EBMT)848patients have been registered,with an over-all survival of81Æ2%at10years(Fig.1;courtesy of Riccardo Saccardi,Chair,EBMT Working Party).The proce-dure’s safety has been steadily increasing,although treat-ment-related mortality(TRM)was still high(23%)in a recent study in severe systemic sclerosis[29].No attempt will be made here to review the results in the various AD,in view of a special issue of Autoimmunity which is in preparation [30].Notwithstanding the common feature of immune reactiv-ity against self,the extreme heterogeneity of human AD sug-gest great caution in drawing,or even attempting conclusions from the available clinical material.It is clear that severe,re-fractory or constantly relapsing SADs have been the mean tar-get up to now,although there is a growing tendency to treat aggressive disease in earlier stages,when there is less irrevers-ible multiorgan damage.3.1.Conditioning regimensIntensive myeloablative regimens were generally utilized with the intent to eliminate‘‘the last autoimmune clone’’. This type of approach is based on the critical need for tumor cell eradication for successful therapy of malignant diseases [31],generally obtained by combination therapy including chemo-radiotherapy and immune reactions following allo-SCT.However the target of the conditioning regimens for SADs is the immune system,which can be reached more spe-cifically by lymphoablative,less toxic regimens[32].On the other hand a multicenter retrospective study by the EBMT has shown a higher relapse rate with less intensive and less toxic regimens,and a higher TRM but longer remissions with high-intensity regimens[33].A randomized prospective study is being currently performed in Genoa in MS patients, to compare the intensive,widely utilized BEAM regimen with a‘‘light’’protocol(CY120mg/kg in2days followed by ATG 3.75mg/kg)for2days(G.L:Mancardi,personal communication).For the time being,however,the controversy surrounding the competition between lymphoablative versus myeloablative(or perhaps intensive versus reduced intensity) regimens has yet to be resolved[32].In addition,for both par-adigms of SCT,auto-and allo,differently from oncohemato-logic diseases in which the biological pronouncement of cure now relies on molecular criteria,in ADs only biomarkers and surrogates can be utilized[34].3.2.Mechanism of actionNotwithstanding intensive investigations there are still un-answered questions.That pharmacological immunedebulking Fig.1.Overall survival of848patients with severe autoimmune diseases hav-ing been treated with autologous hematopoietic stem cell transplantation and registered by the Working Party of the European Blood and Marrow Trans-plantation Group(EBMT).Courtesy by Dr.Riccardo Saccardi.146 A.M.Marmont/Journal of Autoimmunity30(2008)145e150is important is certain,as confirmed both the formerly mentioned longer remissions following more intense condi-tioning[33],and the results with high-dose CY alone[35]. However immune reconstruction is tightly related to former immunoablation both for non-autoimmune(which will not be considered here)and autoimmune conditions[36].In my-elin-oligodendrocyte-glycoprotein(MOG)induced EAE in rats,a protective effect was achieved by allogeneic and syn-geneic BM grafts also from diseased rats.These effects were consistent with increased numbers of CD4þCD25 (bright)regulatory T cells and,interestingly with a strong re-duction of autoantibodies even after rechallenge with MOG, indicating long-lasting B cell tolerance[37].In the clinic, a prolonged depression of CD4þCD45RA T cells is a general finding,and takes place in all situations following SCT,auto-immune included[38].What type of immunomodulation then follows has been investigated intensively,and what has been called a‘‘black box’’by Muraro and Douek[39]is becoming gradually clearer,although there appears to be some degree of contradiction.Most studies have been performed in patients with MS following ASCT.In afirst one,the T cells recogniz-ing the antigen,myelin basic protein(MBP),were depleted following immunoablation.By the end of thefirst year,how-ever,new BMP-reactive T cells,originating from na€ıve T cells,could be detected[40].This cannot be considered solely as the presence of minimal residual autoimmune disease (MRAD),but implies also the persistence of an antigenic challenge[41].Other recent studies,based on phenotype and T cells excision circles(TREC),showed a new and di-verse TCR repertoire after ASCT[42].A rebuilding of the immune system has been proposed,in a way that is less likely to redevelop autoimmunity[39].In juvenile idiopathic arthri-tis(JIA)the autoimmune cells were shown to deviate from proinflammatory phenotype to a tolerant one following ASCT[43].These immune changes are integrated by the dy-namics of new important players such a regulatory and mes-enchimal cells,which are an important component of cell therapy for AD[44].A clear distinction must be made be-tween the good,at times excellent,clinical results,with pro-longed remissions,and restored sensitivity to formerly inactive drugs,and the biological significance of the‘‘reset-ting’’of the immunological clock.One may wonder,however, whether the interaction between the original autoimmune im-printing and the persistent autoantigenic challenges will not finally cause biological and clinical relapse,negating the con-cept of‘‘cure’’.4.Allogeneic hematopoietic stem cell transplantationMore cogently than for the autologous procedure,animal experiments and results from coincidental disease patients [7]have focussed on allo-SCT.As stated in a2005Interna-tional Workshop[45],‘‘the potential for1-time delivery of a curative strategy is appealing’’.This has been clearly demon-strated for a blood and marrow disease such as aplastic ane-mia,in which an important autoimmune pathogenesis is recognized[46],but it is still to be evaluated in more typical ADs,such as those that were discussed in the Workshop (MS,RA,SSc,SLE).Allo-SCT is traditionally regarded as a‘‘platform for im-munotherapy’’[47],and a masterful analysis of the mecha-nisms by which allo-SCT might cure AD has been recently performed by Sykes and Nikolic[48],with a Graft-versus-Autoimmunity(GVA)effect in pole position.However the recognition of this effect has started with clinical evidence.A retrospective study,re-echoing basic concepts in allo-SCT for malignancies,showed that there were more relapses of co-incidental ADs in patients transplanted for haematologic malignancies with no GVHD,than in those who developed it[49].In addition,there is a group of single case reports in which donor lymphocyte infusions(DLI)were necessary to achieve full donor chimerism,which was associated with complete remission of the AD[50e53].This is in contrast with the hypothesis that mixed chimerism might be capable of inducing long-term remissions[54,55].These clinical re-sults have been considerably reinforced by a recent,elegant study in mice,in which it was shown that allogeneic,but not syngeneic BMT conferred protection from EAE,but that this required high-level donor chimerism from EAE-resistant donors[56].Importantly,when EAE-susceptible donors were utilized,robust protection from EAE was obtained when active alloreactivity,induced by donor lymphocyte infusions,was provided.Independently from genetic susceptibility,active al-loreactivity was associated with a GV A effect.In addition to the problems associated with allo-SCT for human ADs,with special reference to GVHD(the occurrence of GVHD in a patient transplanted with PBSC for SSc would be disastrous!),further perplexities emerge from case reports of patients with SADs having received allogeneic SCT,and having relapsed notwithstanding full donor chimerism.The first2were patients with RA,transplanted because of severe iatrogenic aplastic anemia[57]or multiple myeloma[58]. Both of them were cured of their hematological disease,but relapsed of their RA.A most demonstrative case is a patient with Evans syndrome who had originally responded well to DLI,but unfortunately relapsed and died5years later[59]. The patient was male and had received the bone marrow of his HLA-identical sister.The immunoglobulins(IgG,IgM) eluted from his100%XX expanded B cells were not the ones eluted from his Coombs-positive cells.It was hypothe-sized that the autoantibodies might have been secreted by long-lived host plasmacytes surviving in postulated marrow niches[60].Even allowing for the hypothesis that relapses in donor cells in patients transplanted for leukemia might be less uncommon than generally thought to be[61,62],it is still an extremely rare event,having been identified in14out of 10,489transplants in a recent survey[63].In contrast,3re-lapses in the much smaller group of autoimmune allotrans-planted patients inevitably causes some perplexity[64].Only further careful clinical investigations will hopefully elucidate this unexpected problem.Syngeneic transplants(admittedly a niche event)have been utilized for few patients.Three patients with RA received syn-geneic transplants following high-dose immunosuppression.147A.M.Marmont/Journal of Autoimmunity30(2008)145e150Thefirst was a patient with severe seronegative RA,who en-joyed a long-term remission[65].However a second patient with progressively erosive,rheumatoid factor positive RA, who was treated with high-dose CY and received an unmanip-ulated peripheral blood graft(PBSCT)from her identical twin sister,had a poor clinical response,associated with persistence of autoantibodies[66].A still unpublished case is the one of 45year old lady with severe seropositive RA was transplanted in Genoa from her identical twin sister on July29,2005.The conditioning regimen consisted in CY,160mg/Kg.Both rheu-matoid factor and anti-cyclic citrulline peptide(CCP)titres decreased significantly(CCP from234to2),but there was a clinical relapse with fever,polyarthritis and elevation of ESR,requiring further treatment.A splenectomised patient with chronic autoimmune thrombocytopenic purpura(AITP) went into complete long-term remission following PBSCT fol-lowing a syngeneic transplant[67].Finally,an entirely different approach consists in the strat-egy of engineering SC to express the culprit self-antigen,in order to achieve permanent immune tolerance[68,69].This approach would seem preferentially directed to organ-specific ADs,with a single(or near-single)autoantigen to be tolerized.5.ConclusionsDiscussing the advantages and disadvantages of ASCT for autoimmune rheumatic diseases Illei has recently posed the classical question,whether the glass is half full or half empty [70].An attempt to answer Illei’s question follows.The full-ness is represented by its powerful disease-arresting potential, and by the resetting the clinical(easier management)and bio-logical(immune re-education?)clock.The emptiness is some degree of toxicity,which is counterbalanced by the severity of the disease,and by the knowledge that no real cure can be re-alistically expected.Only the ongoing prospective randomised trials will be able to state whether ASCT is still superior to the new biological and pharmacological therapies.The experience with syngeneic transplants is too scarce, and perhaps not so encouraging as initially hoped.In a disease which may become a target for allo-SCT such as SLE,a recent study of247sets of twins has found that there was a60%con-cordance of disease in151sets of monozygotic(MZ)twins, while only4out of96dyzigotic(DZ)sets were concordant [71].These results must be taken in consideration before plan-ning this type of strategy.Allogeneic SCT,with its ability to provide a new immune system and a GVA effect,is attractive,and will be certainly performed utilizing reduced intensity conditioning(RIC) regimens,but the hazards of GVHD and unexpected relapses suggest great caution.Whether the achievement of GV A di-vorced from GVH[72]e a perennial but elusive goal of trans-planters for oncohematological diseases-will be obtainable will require further experience.For additional readings on the use of bone marrow transplantation for autoimmunity, we refer the reader to the companion papers published in this special issue[73e83].References[1]Rose NR,Mackay IR,editors.The autoimmune diseases.Amsterdam-Tokyo:Elsevier;2006.[2]Rose NR,Bona C.Defining criteria for autoimmune diseases(Witebsky’spostulates revisited).Immunol Today1993;14:426e8.[3]Marmont AM.Defining criteria for autoimmune diseases.ImmunolToday1994;15:388.[4]Chatenoud L.Emerging therapies for autoimmune diseases.In:Rose NR,Mackay IR,editors.The autoimmune diseases.Amsterdam-Tokyo: Elsevier;2006.p.1063e81.[5]Burt RK,Slavin S,Burns WH,Marmont AM.Induction of tolerance inautoimmune disease by hematopoietic stem cell transplantation:getting closer to a cure?Blood2002;99:768e84.[6]Goodnow CC,Sprent J,Fazekas de St Groth B,Vinnesa CG.Cellular andgenetic mechanisms of self tolerance and autoimmunity.Nature 2005;435:590e7.[7]Marmont AM.Introduction to stem cell transplantation for autoimmunediseases.Autoimmunity,in press.[8]Marmont AM.Coincidental autoimmune disease in patients transplantedfor conventional indications.Best Pract Res Clin Haematol2004;17: 223e32.[9]Burt RK,Marmont AM,editors.Stem cell therapy for autoimmunedisease.Georgetown:Landes Bioscience;2004.[10]Gratwohl A,Tyndall A,editors.Stem cell transplantation for autoim-mune disorders.Best Pract Res Clin Haematol,17;2004.p.199e374.[11]Kapoor S,Wilson AG,Sharrack B,Lord A,Akil M,Lingyun S,et al.Hematopoietic stem cell transplantation-an evolving treatment for severe autoimmune and inflammatory diseases in rheumatology,neurology and gastroenterology.Hematology2007;12:179e91.[12]Marmont AM.Lupus:tinkering with haematopoietic stem cells.Lupus2001;10:769e74.[13]Levite M,Zinger H,Mozes I,Reisner Y,et al.Systemic lupus erythema-tosus-related antibody production in mice is determined by marrow derived cells.Bone Marrow Transplant1993;12:179e83.[14]Reininger I,Radkiewiecs T,Kosco E.Development of autoimmunedisease in SCID mice populated with long-term‘‘in vitro’’proliferating (NZBÂNZW)F1pre-B cells.J Exper Med1992;176:1343e53. [15]Ikehara S.Treatment of autoimmune diseases by hematopoietic bonemarrow transplantation.Exp Hematol2001;29:661e9.[16]Ende N,Czarnesky J,Raveche E.Effect of human cord blood transfer onsurvival and disease activity in MRL-Ipr mice.Clin Immunol Immunopa-thol1995;75:190e5.[17]Ikehara S.A novel strategy for allogeneic stem cell transplantation:perfusion method plus intra-bone marrow injection stem cells.Exp Hematol2003;31:1142e6.[18]Ikehara S.Intra-bone marrow marrow-bone marrow transplantation.Anew strategy for treatment of stem cell disorders.Ann NY Acad Sci 2005;1051:626e34.[19]Castello S,Podesta`M,Mendillo VG,Ibatici A,Pitto A,Figari O,et al.Intra-bone marrow injection of bone marrow and cord blood cells.An al-ternative way of transplantation associated with a higher seeding effi-ciency.Exp Hematol2004;32:782e7.[20]Kushida T,Inaba M,Hischa H,Ichioka N,Esumi T,Ogawa R,et al.In-tra-bone marrow injection of allogeneic marrow cells:a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice.Blood2001;97:3292e9.[21]Li C,He Y,Feng X,Adachi Y,Takada K,Zhang Y,et al.An innovativeapproach to bone marrow collection and transplantation in a patient with B-thalassemia major:collection using a perfusion method followed by intra-bone marrow injection collected bone marrow cells.Int J Hematol 2007;85:73e7.[22]Namjou B,Kelly JA,Harley JB.The genetics of lupus.In:Tsokos GC,Gordon C,Smolen JS,editors.Systemic lupus erythematosus.Mosby-Elsevier;2007.p.74e86.[23]Ermann J,Fathman CG.autoimmune diseases:genes,bugs and failedregulation.Nature Immunol2002;2:759e66.148 A.M.Marmont/Journal of Autoimmunity30(2008)145e150[24]Van Bekkum DW.Stem cell transplantation for autoimmune disorders.Pre-clinical experiments.Best Pract Res Clin Haematol2004;17: 201e22.[25]Ikehara S,Kawamura M,Takao F,Inaba M,Yasumizu R,Than S,et al.Organ-specific and systemic autoimmune diseases originate from defects in haematopoietic stem cells.Proc Natl Acad Sci1990;87:8341e4. [26]Marmont AM,van Lint MT,Gualandi F,Bacigalupo A,et al.Autologousmarrow stem cell transplantation for systemic lupus erythematosus of long duration.Lupus1997;6:545e8.[27]Loh Y,Oyama Y,Statkute L,Quigley K,Yaung K,Gonda F,et al.De-velopment of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases:role of conditioning regimen used.Blood2007;109:2643e8.[28]Marmont AM.History perspective and rationale of HSCT forautoimmune diseases.In:Burt RK,Marmont AM,editors.Stem cell therapy for autoimmune ndes Bioscience2004:223e33. [29]Nash RA,Mc Sweeney P,Crofford LJ,Abidi M,Chen C-S,Godwin JD,et al.High-dose immunosuppressive therapy and autologous hematopoi-etic cell transplantation for severe systemic sclerosis:long-term follow-up of the US multicenter study.Blood2007;110:1388e96.[30]Marmont AM,Saccardi R,editors.Haematopoietic stem cell transplanta-tion for severe autoimmune diseases.Autoimmunity,in press.[31]Dingli D,Michor F.Successful therapy must eradicate cancer stem cells.Stem Cells2006;24:2603e10.[32]Burt RK,Marmont AM,Oyama Y,Slavin S,Arnold R,Hiepe F,et al.Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases.The evolution from myeloabla-tive to lymphoablative transplant regimens.Arthritis Rheum Arthritis Rheum2006;54:3750e60.[33]Gratwohl A,Passweg J,Bocelli-Tyndall C,Fassas A,van Laar JM,Farge D,et al.Autologous hematopoietic stem cell transplantation for au-toimmune diseases.Bone Marrow Transplant2005;35:869e79. [34]Schiffenbauer J,Hahn B,Weisman MH,Simon LS.Biomarkers,surrogate markers,and design of clinical trials of new therapies for systemic lupus erythematosus.Arthritis Rheum2004;50:2415e22. [35]Petri M,Brodsky R.High-dose cyclophosphamide and stem celltransplantation for refractory systemic lupus erythematosus.JAMA 2006;295:559e60.[36]Isaacs JD,Thiel A.Immune reconstitution.Best Pract Res Clin Haematol2004;17:345e58.[37]Herrmann MM,Gaertner S,Stadelmann C,van den Brandt R,Boscke R,Budach W,et al.Tolerance induction by bone marrow transplantation ina multiple sclerosis model.Blood2005;106:875e83.[38]Gualandi F,Bruno B,van Lint MT,Lucchetti S,Uccelli A,Capello E,et al.Autologous stem cell transplantation for severe autoimmune dis-ease.A10-year experience.Ann NY Acad Sci2007;1110:455e64. [39]Muraro P,Douek DC.Renewing the T cell repertoire to arrest immuneaggression.Trends Immunol2006;27:61e7.[40]Sun W,Popat V,Hutton G,Ying C,Zang CQ,Krance R,et al.Charac-teristics of T-cell receptor repertoire and myelin-reactive T cells reconsti-tuted from autologous haematopoietic stem-cell grafts in multiple sclerosis.Brain2004;127:996e1008.[41]Brenner MK.Haematopoietic stem cell transplantation for autoimmunedisease:limits and future potential.Best Pract Res Clin Haematol 2004;17:359e74.[42]Muraro PA,Douek DC,Packer A,Chung K,Guenaga FJ,Cassiani-lngoni R,et al.Thymic output generates a new and diverse TCR reper-toire after autologous stem cell transplantation in multiple sclerosis patients.J Exper Med2005;201:805e16.[43]De Kleer I,Vastert B,Klein M,Teklenburg G,Arkestejn G,Yung P,et al.Autologous stem cell transplantation for autoimmunity induces immuno-logic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+immune regulatory network.Blood2006;107: 1696e702.[44]Dazzi F,van Laar JM,Cope A,Tyndall A.Cell therapy for autoimmunediseases.Arthritis Res Ther2007;9:206e15.[45]Griffith LM,Pavletic SZ,Tyndall A,Bredeson CN,Bowen JO,Childs RW,et al.Feasibility of allogeneic hematopoietic stem celltransplantation for autoimmune disease:position statement from a Na-tional Cancer Institute sponsored International Workshop.Bethesda, MD,March12&13,2005.Biol Blood Marrow Transplant2005;11: 862e70.[46]Young NS,Calado RT,Scheinberg P.Current concepts in the pathophys-iology and treatment of aplastic anemia.Blood2006;108:2500e19. [47]Appelbaum FR.Hematopoietic stem cell transplantation as immunotherapy.Nat Med2000;411:385e9.[48]Sykes M,Nikolic B.Treatment of severe autoimmune disease by stem-cell transplantation.Nature2005;435:620e6.[49]Hinterberger W,Hinterberger-Fischer M,Marmont AM.Clinicallydemonstrable anti-autoimmunity mediated by allogeneic immune cells favourably effects outcome after stem cell transplantation in human autoimmune diseases.Bone Marrow Transplant2002;30:753e9. [50]Marmont AM,Gualandi F,van Lint MT,Bacigalupo A.Refractory Evanssyndrome treated with allogeneic SCT followed by DLI.Demonstration of a graft-versus-autoimmunity effect.Bone Marrow Transplant2003;31: 399e401.[51]Musso M,Porretto F,Crescimanno A,Polizzi V,Scalone R,et al.Donorlymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and allogeneic peripheral stem cell transplantation.Bone Marrow Transplant2004;33:769e71.[52]Hayden PJ,Grampe M,Lawler M,Sedor JR,et e of DLI to achievecomplete donor chimerism in a patient receiving systemic immunosup-pression for refractory AIHA post-NST.Bone Marrow Transplant 2005;36:735e6.[53]Marmont AM,Dominietto A,Gualandi F,Piaggio G,van Lint MT,Bacigalupo A,et al.Pure white cell aplasia(PWCA)relapsing after al-logeneic BMT and successfully treated with nine DLI.Biol Blood Marrow Transplant2006;12:987e9.[54]Chakrabarti S,Handa SK,Byron RJ,Griffiths MJ,Milligan DW,et al.Will mixed chimerism cure autoimmune diseases after a nonmyeloabla-tive stem cell transplant?Transplantation2001;72:340e2.[55]Burt RK,Oyama Y,Verda L,Quigley K,Brush M,Yaung K,et al.Induc-tion of remission of severe and refractory rheumatoid arthritis by alloge-neic mixed chimerism.Arthritis Rheum2004;50:2466e70.[56]van Wijmeersch B,Sprangers B,Rutgeers O,Lenaerts C,Landuyt W,Waer M,et al.Allogeneic bone marrow transplantation in models of ex-perimental autoimmune encephalomyelitis:evidence for a Graft-versus-Autoimmunity effect.Biol Blood Marrow Transplant2007;13:627e37.[57]McKendry RJR,Huebsch L,Le Clair B.Progression of rheumatoidarthritis following bone marrow transplantation:a case report with a13year follow-up.Arthritis Rheum1996;39:1246e53.[58]Tapprich C,Feuk RR,Schneider P,Bernhardt A,Haas R,Kobbe G,et al.Early recurrence of rheumatoid arthritis after non myeloablative alloge-neic blood stem cell transplantation in a patient with multiple myeloma.Bone Marrow Transplant2003;32:629e31.[59]Marmont AM,Gualandi F,Occhini D,Morandi F,Ferretti E,Pezzolo A,et al.Catastrophic relapse of Evans syndromefive years after allogeneic BMT notwithstanding full donor chimerism.Terminal haemolytic-uremic syndrome.Autoimmunity2006;39:505e11.[60]Hoyer BE,Manz RA,Radbruch A,Hiepe F.Long-lived plasma cells andtheir contribution to autoimmunity.Ann NY Acad Sci2005;1050: 124e33.[61]Flynn CM,Kaufman DS.Donor cell leukaemia:insight into cancer stemcells and the stem cell niche.Blood2007;109:2688e92.[62]McCann S,Wright E.Donor leukaemia:perhaps a more common eventthan we thought!.Bone Marrow Transplant2003;32:455e7.[63]Hertenstein B,Hambach L,Bacigalupo A,Schmitz N,McCann S,Sjavin S,et al.Development of leukemia in donor cells after allogeneic stem cell transplantation e a survey of the European Group for Blood and Marrow Transplantation(EBMT).Haematologica2005;90:969e75.[64]Marmont AM.Allogeneic haematopoietic stem cell transplantation forsevere autoimmune diseases:great expectations but controversial evidence.Bone Marrow Transplant2006;38:1e4.[65]McColl G,Koshaka H,Wicks I.High-dose chemotherapy and syngeneichemopoietic stem cell transplantation for severe seronegative rheumatoid arthritis.Ann Intern Med1999;131:550e3.149A.M.Marmont/Journal of Autoimmunity30(2008)145e150。
期刊简称

Tellus. Series B, Chemical and physical meteorology
地球,B辑:化学气象学与物理气象学
Tellus, Ser. B, Chem. phys. meteorol.
Theoretical and applied climatology
中国海洋大学学报
Journal of Ocean University of China
中国海洋大学学报(英文版)
Marine georesources & geotechnology
海洋地资源与土工学
Mar. georesour. geotechnol.
Marine science bulletin
资源地质
Reviews in mineralogy and geochemistry
矿物学与地球化学评论
Revista geológica de América Central
中美洲地质杂志
Rocky Mountain geology
落基山脉地质学
Scripta geologica
地质学论丛
Scr. geol.
海洋科学通报
New Zealand journal of marine and freshwater research
新西兰海洋与淡水研究杂志
N. Z. j. mar. freshwater res.
Ocean news & technology
海洋新闻与技术
Ocean news technol.
Proceedings of the Institution of Mechanical Engineers:PartM, Journal of engineering for the maritime environment
所有期刊名及其简写-B(3)

所有期刊名及其简写-B"Biochimica et Biophysica Acta, Enzymology" "Biochim. Biophys. Acta, Enzymol. " "Biochim Biophys Acta, Enzymol ""Biochimica et Biophysica Acta, Enzymology and Biological Oxidation" "Biochim. Biophys. Acta, Enzymol. Biol. Oxid. ""Biochim Biophys Acta, Enzymol Biol Oxid ""Biochimica et Biophysica Acta, General Subjects""Biochim. Biophys. Acta, Gen. Subj. " "Biochim Biophys Acta, Gen Subj ""Biochimica et Biophysica Acta, Gene Regulatory Mechanisms" "Biochim. Biophys. Acta, Gene Regul. Mech. ""Biochim Biophys Acta, Gene Regul Mech ""Biochimica et Biophysica Acta, Gene Structure and Expression" "Biochim. Biophys. Acta, Gene Struct. Expression " "Biochim Biophys Acta, Gene Struct Expression ""Biochimica et Biophysica Acta, Lipids and Lipid Metabolism" "Biochim. Biophys. Acta, Lipids Lipid Metab. ""Biochim Biophys Acta, Lipids Lipid Metab ""Biochimica et Biophysica Acta, Molecular Basis of Disease" "Biochim. Biophys. Acta, Mol. Basis Dis. ""Biochim Biophys Acta, Mol Basis Dis ""Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids" "Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids" "Biochim Biophys Acta, Mol Cell Biol Lipids ""Biochimica et Biophysica Acta, Molecular Cell Research""Biochim. Biophys. Acta, Mol. Cell. Res. " "Biochim Biophys Acta, Mol Cell Res ""Biochimica et Biophysica Acta, Mucoproteins and Mucopolysaccharides" "Biochim. Biophys. Acta, Mucroproteins Mucopolysaccharides " "Biochim Biophys Acta, Mucroproteins Mucopolysaccharides ""Biochimica et Biophysica Acta, Nucleic Acids and Protein Synthesis" "Biochim. Biophys. Acta, Nucleic Acids Protein Synth. " "Biochim Biophys Acta, Nucleic Acids Protein Synth ""Biochimica et Biophysica Acta, Protein Structure""Biochim. Biophys. Acta, Protein Struct. " "Biochim Biophys Acta, Protein Struct ""Biochimica et Biophysica Acta, Protein Structure and Molecular Enzymology" "Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. " "Biochim Biophys Acta, Protein Struct Mol Enzymol ""Biochimica et Biophysica Acta, Proteins and Proteomics""Biochim. Biophys. Acta, Proteins Proteomics " "Biochim Biophys Acta, Proteins Proteomics ""Biochimica et Biophysica Acta, Reviews on Bioenergetics""Biochim. Biophys. Acta, Rev. Bioenerg. " "Biochim Biophys Acta, Rev Bioenerg ""Biochimica et Biophysica Acta, Reviews on Biomembranes""Biochim. Biophys. Acta, Rev. Biomembr. " "Biochim Biophys Acta, Rev Biomembr ""Biochimica et Biophysica Acta, Reviews on Cancer""Biochim. Biophys. Acta, Rev. Cancer " "Biochim Biophys Acta, Rev Cancer "Bioconjugate Chemistry Bioconjugate Chem.Bioconjugate ChemBiocontrol Science Biocontrol Sci. Biocontrol Sci Biocontrol Science and Technology Biocontrol Sci. Technol. Biocontrol Sci TechnolBioelectrochemistry and Bioenergetics Bioelectrochem. Bioenerg. Bioelectrochem Bioenerg"Biofuels, Bioproducts and Biorefining" "Biofuels, Bioprod. Biorefin. " "Biofuels, Bioprod Biorefin "Biogenic Amines Biog. Amines Biog AminesBioinformatics and Biology Insights Bioinf. Biol. Insights Bioinf Biol InsightsBioinspiration & Biomimetics Bioinspiration Biomimetics Bioinspiration Biomimetics。
【完整版毕业论文】郑州大学研究生在学期间发表论文的基本要求

目录一、文学院 (1)二、历史学院 (4)三、法学院 (8)四、马克思主义学院 (11)五、化学系 (14)六、物理工程学院 (29)七、数学系 (36)八、材料科学与工程学院 (37)九、电气工程学院 (43)十、水利与环境学院 (48)十一、土木工程学院 (55)十二、信息工程学院 (60)十三、化工与能源学院 (67)十四、药学院 (82)十五、基础医学院 (83)十六、公共卫生学院 (87)十七、一附院 (97)十八、二附院 (104)十九、三附院 (108)一、文学院中国古典文献学学科博士生在学期间发表论文期刊目录类别:A类中国古典文献学学科博士生在学期间发表论文期刊目录类别:B+类类别:B类备注及相关说明:一、博士研究生1.、博士研究生在学期间应至少在A类中文核心期刊上发表1篇与本专业有关的学术论文,或至少必须在B类中文核心期刊上发表2篇与本专业有关的学术论文,其中有1篇必须发表在B+期刊上。
2、在《人民日报》、《光明日报》理论版发表学术论文1篇,等同于在B+类中文核心期刊发表1篇学术论文。
3、与学位论文相关的科研成果获得省部级以上奖励或地厅级一等以上奖励(排名前3,署名郑州大学)1项,等同于在B类中文核心期刊上发表论文1篇。
二、硕士研究生1、硕士研究生应在CN以上学术刊物或者公开出版物上发表与本专业有关的学术论文1篇(不含增刊)。
2、凡要求提前毕业的硕士研究生,应在学术刊物上发表学术论文2篇以上,其中1篇必须为国家级期刊。
三、其他说明1、研究生在学期间均应以第一作者身份(或导师为第一作者,本人为第二作者),且以郑州大学为第一著作单位,按上述要求发表与本专业研究相关的学术论文后方可申请学位。
2、如果研究生申请答辩时未满足上述要求,但满足毕业条件的,允许组织学位论文答辩。
答辩通过者,可先予以毕业,但分委员会暂不审议其学位,直至在规定期限内(博士生毕业后两年,硕士生毕业后一年)满足发表论文的基本要求后,再由本人申请审议其学位。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
Guest Editorial Toward Molecular ImagingR ECENTLY,molecular imaging has attracted great interest and been widely recognized as a major trend of biomed-ical imaging.According to Weissleder and Mahmood[1],“The term molecular imaging can be broadly defined as the in vivo characterization and measurement of biologic processes at the cellular and molecular level.”While traditional biomedical imaging techniques are anatomically/functionally oriented that reflect structural features and physiological/pathological phenomena,the purpose of molecular imaging is to detect,cap-ture,and monitor molecular/cellular abnormalities in vivo that cause diseases and associated symptoms.Hopefully,sensitive, specific,and quantitative imaging of such molecular/cellular targets would revolutionize life sciences and clinical prac-tice from the most fundamental level,and bring enormous healthcare benefits in the future.This special issue is an initial response of our journal to the grand challenges in molecular imaging.Ten papers[2]–[11]were selected from21submis-sions as a snap-shot of its state of the art(The last paper[11] was handled by Associate Editor Erik Meijering).Small animals,including genetically engineered mice,are popular models to study human diseases and evaluate therapies. In the post-genome era,the genome is being linked to pheno-typic expressions in forms and functions for development of sys-tems biomedicine.Hence,all medical imaging modalities have been downscaled over past several years.The resultant minia-tures include micro-CT,micro-MRI,micro-PET,micro-SPECT, and micro-ultrasound scanners as well as optical imagers of dif-ferent types for small animal imaging.With molecular imaging of small animals,physiological processes and pathologic pro-gression can now be studied in a compressed period under con-trolled conditions with various probes.As a result,seven papers [2]–[5],[7]–[9]in this special issue are directly related to small animal imaging.As thefirst medical tomographic modality,X-ray CT is not only extensively used for anatomical imaging but also impor-tant for physiologic imaging.In the work by Krishnamurthi et al.[2],functional micro-CT was evaluated for monitoring thera-peutically induced changes at the cellular level.Based on a com-partmental model,they determined the scanning protocols for mouse contrast studies on renal bloodflow,glomerularfiltra-tion rate,fractional plasma volume,fractional tubular volume, and urine formation rate.Then,Surti et al.[3]assessed the per-formance of a small animal3D PET scanner.This micro-PET camera of an axial length of11.9cm can achieve a resolution of1.9mm and a sensitivity of3.6%in the range of250–665 KeV.For micro-SPECT imaging,Metzler et al.coupled a com-mercial triple-head SPECT scanner with pinhole collimation and external transport for high magnification and helical scan-Manuscript received April22,2005.Digital Object Identifier10.1109/TMI.2005.848987ning[4].They used this cost-effective micro-SPECT system to image radio-labeled molecules in phantoms and animals with a spatial resolution of1.6mm.Goertzen et al.replaced the parallel hole collimators of a human SPECT scanner with a multi-pinhole collimator array[5].Their approach allows a bal-ance between resolution and sensitivity,and may be improved for dynamic in vivo imaging.Furthermore,Brzymialkiewicz et al.tested the Cadmium Zinc Telluride detector-based3D emis-sion mammotomography for breast cancer studies[6].They es-timated signal-to-noise ratio and lesion contrast with/without a torso phantom background.Their data show that the3D mam-motomography can reveal tumorsof cm in diameter.As far as optical imaging is concerned,Zacharakis et al.developed a fluorescent protein tomography scanner working at the visible wavelengths to imagefluorescent proteins deep inside a small animal[7].They adopted multi-angle multi-projection illumina-tion and highly sensitive detection strategies.Image reconstruc-tion was based on the diffusion equation modified to accommo-date relatively high absorption,producing sub millimeter spatial resolution in phantoms and tissues.In a broad sense,biomedical imaging means not only data acquisition and image reconstruction but also image processing and analysis.In the paper by Jan et al.[8],three imaging modal-ities,X-ray CT,PET,and SPECT,were combined to map func-tional/cellular/molecular images at low resolution onto the cor-responding anatomy at high resolution for small animal studies. For both the micro-PET-CT fusion and the micro-PET-SPECT fusion,the maximum errors along three axes were generally less than0.5mm.On the other hand,Marias et al.studied registra-tion offluorescent image sequences for monitoring genomics and proteomics over time on the same small animal[9].Their method was based on computed surface landmarks,and com-pensates for differences in the posture and compression/stretch of the subject.In another hot area of molecular imaging—micro-array image analysis,Blekas et al.described a statistical ap-proach for mixture model analysis[10].They devised a girding method to localize individual spots,and assumed a Gaussian mixture model to analyze these spots.Their methodology was evaluated using synthetic and real data in comparison with ex-isting techniques.It seems quite effective,flexible,and robust. Finally,the cells,as building blocks of the life,are of partic-ular interest.Image analysis in this area quantifies cell mor-phology,growth,motility,and responses to perturbation.In the paper by Dong et al.[11],the problem of counting rolling leuko-cytes was solved using intra-vital microscopy and computer-ized post-processing.They proposed“the gradient inverse co-efficient of variation”and a Bayesian classification scheme to discriminate leukocytes from their environment with a detec-tion accuracy of78.6%.Despite the impressive results published in this special issue and other peer journals,molecular imaging is still at its infancy.0278-0062/$20.00©2005IEEETo meet the requirements of individualized molecular medicine, current molecular imaging techniques must be dramatically improved in sensitivity,specificity,resolution,accuracy,and other indexes.Most importantly,issues specific to molecular imaging must be addressed using innovative ways,related to solution nonuniqueness,numerical instability,rather low signal-to-noise ratio,complicated heterogeneity and dynamic processes[12]–[14].Although the future is difficult to predict, we believe promising research paradigms should involve novel probes,sensitive data acquisition,multi-modality multi-mode fusion,advanced reconstruction methods,prior knowledge based regularization,sophisticated image analysis,and/or optimized system integration.There is no doubt that molecular imaging will play an increasingly more important role in basic and clinical research.Toward that goal,we hope that more junior and established investigators will join us to advance this interdisciplinaryfield of unprecedented promises.G E W ANG,Guest EditorUniversity of IowaDepartments of Radiology andBiomedical EngineeringIowa City,IA52242USAR ONALD J.J ASZCZAK,Guest EditorDuke UniversityDepartments of Radiology andBiomedical EngineeringDurham,NC27708USAJ AMES P.B ASILION,Guest EditorHarvard Medical School andMassachusetts General HospitalBoston,MA02114USAR EFERENCES[1]R.Weissleder and U.Mahmood,“Molecular imaging,”Radiology,vol.219,pp.316–333,2001.[2]G.Krishnamurthi,K.M.Stantz,R.Steinmetz,G.D.Hutchins,and Y.Liang,“Functional imaging in small animals using X-ray computed to-mography—Study of physiologic measurement reproducibility,”IEEE Trans.Med.Imag.,vol.24,no.7,Jul.2005.[3]S.Surti,J.S.Karp,A.E.Perkins,C.A.Cardi,M.E.Daube-Wither-spoon,A.Kuhn,and G.Muehllehner,“Imaging performance of A-PET:A small animal PET camera,”IEEE Trans.Med.Imag.,vol.24,no.7,Jul.2005.[4]S.D.Metzler,R.J.Jaszczak,N.H.Patil,S.Vemulapalli,G.Akabani,and B.B.Chin,“Molecular imaging of small animals with a triple-head SPECT system using pinhole collimation,”IEEE Trans.Med.Imag.,vol.24,no.7,Jul.2005.[5] A.L.Goertzen,D.W.Jones,J.Seidel,K.Li,and M.V.Green,“Firstresults from the high-resolution mouse SPECT annular scintillation camera,”IEEE Trans.Med.Imag.,vol.24,no.7,Jul.2005.[6] C.N.Brzymialkiewicz,M.P.Tornai,R.L.McKinley,and J.E.Bowsher,“Evaluation of fully3D emission mammotomography with a compact Cadmium Zinc Telluride detector,”IEEE Trans.Med.Imag.,vol.24,no.7,Jul.2005.[7]G.Zacharakis,J.Ripoll,R.Weissleder,and V.Ntziachristos,“Fluo-rescent protein tomography scanner for small animal imaging,”IEEE Trans.Med.Imag.,vol.24,no.7,Jul.2005.[8]M.L.Jan,K.S.Chuang,G.W.Chen,Y.C.Ni,S.Chen,C.H.Chang,J.Wu,T.W.Lee,and Y.K.Fu,“A three-dimensional registration technique for automated fusion of micro PET-CT-SPECT whole-body images,”IEEE Trans.Med.Imag.,vol.24,no.7,Jul.2005.[9]K.Marias,J.Ripoll,H.Meyer,V.Ntziachristos,and S.Orphanoudakis,“Image analysis for assessing molecular activity changes in time-depen-dent geometries,”IEEE Trans.Med.Imag.,vol.24,no.7,Jul.2005. [10]K.Blekas,N.P.Galatsanos,A.Likas,and garis,“Mixture modelanalysis of DNA microarray images,”IEEE Trans.Med.Imag.,vol.24, no.7,Jul.2005.[11]G.Dong,N.Ray,and S.T.Acton,“Intravital leukocyte detection usingthe gradient inverse coefficient of variation,”IEEE Trans.Med.Imag., vol.24,no.7,Jul.2005.[12] D.S.Holder,Electrical Impedance Tomography.Bristol,PA:Inst.Phys.,2005.[13]G.Wang,Y.Li,and M.Jiang,“Uniqueness theorems in bioluminescencetomography,”Med.Phys.,vol.31,pp.2289–2299,2004.[14]V.Ntziachristos,J.Ripoll,L.V.Wang,and R.Weissleder,“Lookingand listening to light:The evolution of whole-body photonic imaging,”Nature Biotechnol.,vol.23,pp.313–320,2005.Ge Wang(S’90–M’92–SM’00–F’03)received the B.Eng.degree in electrical engineering fromXidian University,Xian,China,in1982,the M.S.degree in remote sensing from Graduate Schoolof Academia Sinica,Beijing,China,in1985,and the M.S.and Ph.D.degrees in electrical andcomputer engineering from State University of New York,Buffalo,in1991and1992.He was Instructor and Assistant Professor with Department of Electrical Engineering,GraduateSchool of Academia Sinica in1984–1988,Instructor and Assistant Professor with MallinckrodtInstitute of Radiology,Washington University,St.Louis,MO,in1992-1996.He was AssociateProfessor with University of Iowa from1997-2002.Currently,he is Professor with Departmentsof Radiology,Biomedical Engineering,Civil Engineering,and Mathematics,and Director of theCenter for X-Ray and Optical Tomography,University of Iowa.His interests include computedtomography,bioluminescence tomography,and systems biomedicine.He has authored or coau-thored over300journal articles and conference papers,including thefirst paper on spiral/helicalcone-beam CT and thefirst paper on bioluminescence tomography.Dr.Wang serves as Editor-in-Chief for the International Journal of Biomedical Imaging,and Associate Editor for IEEE T RANSACTIONS ON M EDICAL I MAGING and Medical Physics,among others.He is an AIMBE Fellow.He has been honored by the 1996Hounsfield Award from Society of Computed Body Tomography and Magnetic Resonance,the1997Giovanni DiChiro Award for Outstanding Scientific Research from the Journal of Computer Assisted Tomography,the1999Medical Physics Travel Award from American Association of Physicists in Medicine,and the2004Herbert Stauffer Award for Outstanding Basic Science Paper in Academic Radiology from Association of University Radiologists.Ronald J.Jaszczak(M’75–SM’91–F’93)received the B.S.degree with high honors in physicsfrom the University of Florida,Gainesville,in1964,ranking4th in a class of980.In1968,hereceived the Ph.D.degree in nuclear physics from the same university.He was awarded a U.S.Atomic Energy Commission Postdoctoral Fellowship at Oak RidgeNational Laboratory in1968and remained in the Physics Division at ORNL as a Staff Physicistuntil1971.He then joined the Research Department at Nuclear Chicago Corporation as a Prin-cipal Research Scientist and became Chief Scientist in1977.In1979,he was recruited to DukeUniversity as an Associate Professor in the Department of Radiology.He is currently a Professorof Radiology and a Professor of Biomedical Engineering.He has contributed to the developmentof single photon emission computed tomography(SPECT)and is credited with coining the termSPECT.In1981,he and his wife,Nancy,co-founded Data Spectrum Corporation,Hillsborough,NC,a leading manufacturer of quality assurance and research phantoms for the nuclear medicalimaging community.He has authored or co-authored over300peer-reviewed journal articles, conference proceedings and book chapters.Dr.Jaszczak has held several appointed and elected positions on the NPSS Administrative Committee(AdCom)including,for example,NPSS President and V.P.He has served as an Associate Editor of IEEE T RANSACTIONS ON M EDICAL I MAGING.In2000, he received the Paul C.Aebersold Award from the Society of Nuclear Medicine for his outstanding achievements in basic sciences applied to nuclear medicine.James P.Basilion received the B.A.degree in biochemistry from the University of Pennsylvania,Philadelphia,in1984,and entered the doctoral program at the Graduate School of BiomedicalSciences,University of Texas Health Science Center at Houston.Following his graduate studies he took a Postdoctoral Fellowship at NIH-NICHD in the CellBiology and Metabolism Branch.During his postdoctoral work he began a series of studies withinvestigators at the Center for Molecular Imaging at Massachusetts General Hospital(MGH)toexploit iron metabolism for molecular imaging.This work resulted in the creation of a trans-gene and magnetic resonance imaging probes suitable for imaging gene transfer and changesin endogenous levels of internalizing receptors in vivo both noninvasively and in real time withmagnetic resonance imaging.In1996,he left the NIH to take a position as a Senior Scientist at asmall genomics/anti-cancer biotech company.In1999,he joined the Faculty of Harvard MedicalSchool and MGH as an Assistant Professor of Radiology.With the Director of the Center forMolecular Imaging,he formed the NFCR Center For Molecular Analysis and Imaging and has been attempting to mine the rich genomic databases with an eye on informing molecular imaging technologies.Currently,he heads a small group of Ph.D.s and physicians that are attempting to identify informative markers and molecular signatures of disease and are developing imaging agents suitable to image simultaneous expression of multiple markers.Dr.Basilion is a member of several societies,has held several offices in the Society for Molecular Imaging,has written numerous reviews on molecular imaging and genomics and holds editorships on three imaging or imaging related journals.In September 2005,he will join the Case Center for Imaging Research as an Associate Professor of Radiology and Biomedical Engineering at Case Western Reserve University.。